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PREFACE
A memorandum of understanding has been signed by two government agencies in the United 
States and Sweden—the Division of Standards Development and Technology Transfer of the 
National Institute for Occupational Safety and Health, U.S. Department o f Health and Human 
Services (DSDTT/NIOSH), and the Criteria Group of Occupational Standard Setting, National 
Institute o f Occupational Health (NIOH) (formerly Research Department o f the National 
Board of Occupational Safety and Health). The purpose o f the memorandum is to exchange 
information and expertise in the area o f occupational safety and health. One product o f this 
agreement is the development o f documents to provide the scientific basis for establishing 
occupational exposure limits. These limits will be developed separately by the two countries 
according to their different national policies.
This document on the health effects o f occupational exposure to chlorobenzene is the fifth 
product of that agreement. This document was written by Dr. Björn Heilman, Department of 
Occupational Medicine, University Hospital, Uppsala, Sweden, and was reviewed by the 
Criteria Group and by DSDTT/NIOSH.
Richard W. Niemeier, Ph.D.
Director/DSDTT
NIOSH
Bo Holmberg, Ph.D. 
Chairman/Criteria Group 
NIOH
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BUA Beratergremium fiir umweltrelevante Altstoffe der Gesellschaft Deutscher
Chemiker (Germany)
b.wt. body weight
CNS central nervous system
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HD highest dose group
HPLC high performance liquid chromatography
IBT International Bio-Test Inc. (USA)
IARC International Agency for Research on Cancer
i.p. intraperitoneal (injection)
i.v. intravenous (injection)
LC50 the concentration (in air or water) needed to produce death in 50 percent
of exposed animals; in the present document LC50 refers to inhalation 
concentration
LD50 the dose o f chemical needed to produce death in 50 percent o f dosed
animals
LOEL lowest observed effect level
m- meta- (positions 1,3- in a disubstituted ring structure)
MD medium dose group
NIOH National Institute o f Occupational Health (Sweden)













no observed adverse effect level
no observed effect level
National Toxicology Program (USA)
ortho- (positions 1,2- in a disubstituted ring structure)
Occupational Safety and Health Administration (USA)





threshold limit value (relates to concentration in air at workplaces)
time-weighted average exposure
1 I N T R O D U C T I O N
Chlorobenzene is one of twelve possible chemical species in the group o f chlorinated benzenes 
(36). At room temperature, the substance is a colorless volatile liquid with an odor that has 
been described as “not unpleasant” (63), like that o f “mothballs or benzene” (25) and 
“almondlike” (1, 32). The compound has been used extensively in industry for several years 
and its main use is as a solvent and intermediate in the production of other chemicals (19, 25, 
32). In occupational settings, the main exposure is from inhalation o f the volatile compound.
The present document summarizes and evaluates information that has been considered most 
relevant for the assessment o f the potential adverse health effects from occupational exposure 
to chlorobenzene. To achieve this objective, a literature search was performed in different 
biomedical and toxicological databases (e.g., in Medline; Cancerlit; Toxline; Excerpta Medica; 
National Technical Information Service; Healthline and Chemical Safety Newsbase) before 
the assessment was initiated (July, 1991).
The U.S. Environmental Protection Agency (EPA) has recently prepared a health effects 
criteria document (final draft) for chlorobenzene (32) as well as an updated health effects 
assessment (33). A similar document has also been prepared in Germany (19). These, and 
other reviews (e.g., 2, 6, 25, 68, 92), have been included among the references in the present 
document.
The various health criteria documents mentioned above have included information from 
several unpublished toxicity studies, mainly performed by, or on behalf of, various manufac­
turers of chlorobenzene. Some unpublished investigations are also cited in the present 
document, although the primary sources o f information often were unavailable for critical 
examination. In such a case, this has been indicated with a short remark, provided with the 
citation.
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2 PHYSICAL AND CHEMICAL PROPERTIES
If not stated otherwise, the data on the physical and chemical properties o f chlorobenzene were 
obtained from various reference books and review articles (1, 6, 7, 15, 19, 25, 26, 32, 63). 
Although not always declared, it is assumed that the figures given refer to chlorobenzene of 
analytical quality. Only scarce information on amounts and identities o f potential impurities 
was available. In a teratogenicity study on rats and rabbits (48) using >99.9% pure chloroben­
zene, it was stated that incidental impurities found consisted of benzene (<0.005 %), bromoben- 
zene (0.018%) and water (0.0077%). Chlorobenzene o f technical quality from one of the 
German manufacturers is at least 99.8% pure, containing at most 0.06% dichlorobenzenes and 



















Boiling point [101.3 kPa]: 13-132°C
Melting point: -44.9°C [in ref. (6): -45.6°C]
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Flash point:
Vapor pressure [25 °C]:
Saturation concentration in air [25°C]:
Solidification (freezing) point:
28°C
11.8 mm Hg = 15.81 hPa (25°C) 
8.8 mm Hg « 11.73 hPa (20°C)
1.55% (15,526 ppm)
-55°C
Vapor density [25°C]: 3.88
(air = 1)
Specific density (gravity) [20°C; 25°C]: 1.107
Refractive index [25°C]: 1.5216
Solubility in water: Practically insoluble
(0.049 g/100 ml; 20°C)
Solubility in organic solvents: Freely soluble in alcohol, benzene,
chloroform, diethyl ether













In air: 0.21-0.68 ppm 
In water: 0 .4 -50  fig/1
31 ppm = 4.60 mg/m 
1 mg/m3 = 0.217 ppm
The information on human thresholds for the detection o f chlorobenzene is not uniform. In 
air, the recognition odor has been reported to vary between 0.21 ppm (7) and 0.68 ppm (3 ,92) 
(i.e., between 1 and 3.1 mg/m3). However, in another source o f information (91) it is stated 
that the almondlike odor o f chlorobenzene is barely perceptible at 60 ppm (276 mg/m3). The 
air-dilution threshold given by Amoore and Hautala (3), 0.68 ppm, represents the geometric 
average o f all available literature data, omitting extreme points and duplicate quotations.
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The substance is practically insoluble in water, but the two liquids form an azeotrope that boils 
at 90°C (32). On surface water, chlorobenzene is believed to evaporate rapidly to the air. 
However, due to its greater density, chlorobenzene may also sink to the bottom of still volumes 
of water (32, 39). The reported taste/odor thresholds in water varies between 0 .45-1.5  |jg/l 
(this interval is based on the work by Tarkhova from 1965, cited in references 6 and 32) and 
10-20 pg/1 (based on the work by Varshavskaya from 1967, cited in references 6 and 32), 
respectively. However, these figures were considered difficult to interpret since none o f the 
citations described the experimental conditions employed (32). In another, more recent work, 
the odor threshold for chlorobenzene in water was reported to be 50 jig/1 (3). This so-called 
water-dilution odor threshold value was calculated from the concentration o f the substance in 
water that would generate the air odor threshold (estimated to 0.68 ppm) in the headspace of 
a stoppered flask.
4
3 USES AND OCCURRENCE
The figures given below for production volumes, ambient air levels, etc., have mainly been 
obtained from secondary sources of information (6 ,1 9 ,3 2 ,3 6 ,4 9 ). Consequently, the original 
sources, often unpublished information, have generally not been evaluated in detail.
3.1 Production and  U ses
Like other chlorinated benzenes, monochiorobenzene is commercially produced by the 
chlorination of benzene at an elevated temperature. This is done in the presence o f a 
chlorination catalyst such as ferric chloride (36,39,63). Chlorobenzene may also be produced 
by treating phenol with aqueous sodium hydroxide under high pressure and in the presence of 
chloride (39).
Chlorobenzene is one of the most widely used chlorinated benzenes and it has been the 
dominant commercial isomer for at least 50 years. The compound has been utilized in 
numerous processes. Previously, its main uses were as a chemical intermediate in the synthesis 
of DDT and other organochlorine pesticides, and in the production of phenol and aniline (36, 
92). During the first world war, it was also used in large quantities in the production of picric 
acid, which was utilized as an explosive (92). Its principal use today is as a chemical 
intermediate in the production of chemicals such as nitrochlorobenzenes and diphenyl oxide 
(19, 32, 36). In 1989, 76% of the total amount of chlorobenzene manufactured in the Federal 
Republic of Germany was processed into nitrochlorobenzenes (19). These compounds are 
subsequently used as starting products for crop protection agents, dyestuffs and rubber 
chemicals (19). Chlorobenzene is also used as a solvent in degreasing processes (e.g., in metal 
cleaning operations) and in the dry cleaning industry. It serves as a solvent for paints, 
adhesives, waxes and polishes and has also been used as a heat transfer medium (6, 63, 92) 
and in the manufacture of resins, dyes, perfumes and pesticides (92).
Although the annual production rates for chlorobenzene in the United States [140,000 tons in 
1975; 130,000 tons in 1981 and 116,000 tons in 1984(6 ,32 ,36 ,49 )], show a decreasing trend, 
it has been estimated that the consumption of chlorobenzene would grow at an average annual 
rate of 1-2% in the United States (37). Large manufacturers of chlorobenzene in the United 
States are Monsanto Co., PPG Industries, and Standard Chlorine Chemical Co. (19). In the 
late 1970s, approximately 500 tons of chlorobenzene was imported into the United States (32).
In 1989, a total of 60,000 to 70,000 tons of chlorobenzene was produced in the Federal 
Republic o f Germany by two different manufacturers, Bayer AG and H oechst AG  
(19). In 1985, the total production in Western Europe was estimated to be 82,000 tons 
(19). In Eastern Europe, the total production o f chlorobenzene in 1988 was calculated
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to be 200,000-250,000 tons (19). The production volume in Japan was 28,300 tons in 1988 
(19).
According to the Products Register at the National Chemicals Inspectorate [U. Rick, personal 
communication], monochlorobenzene occurred in ten different chemical products in Sweden 
in 1990. The estimated annual use o f the compound that year in Sweden was 11 to 64 tons. 
There is no production o f chlorobenzene in Sweden.
3.2 O ccupational Exposure and  Ambient Air Levels
The amount of data available with regard to the potential exposure to chlorobenzene in various 
types o f occupational settings is limited. In Sweden, for example, the National Board of 
Occupational Health and Safety (an authority responsible for protecting workers who handle 
chemicals in the workplace from ill-health and accidents) had no information available on the 
present exposure levels o f monochlorobenzene at Swedish workplaces.
A monitoring program of air levels in chlorobenzene- and nitrochlorobenzene-producing 
plants in the United States, which was performed 1978/79, showed that the chlorobenzene 
concentrations varied from not detectable to 18.7 mg/m3 (19). Similar concentrations of 
chlorobenzene have been reported in various field investigations conducted by NIOSH at 
different types of workplaces in the United States (69c-g). In a Japanese study on the urinary 
levels of chlorobenzene-associated metabolites in workers at two different plants handling 
the compound (96), the chlorobenzene levels varied between 7.8-26.7 mg/m3, with a 
geometric mean of 14.5 mg/m3 (3.15 ppm). A similar study from Belgium (56) showed 
variations in chlorobenzene concentrations ranging from 0.2-488 mg/m3, the median value being
5.5 mg/m3 (1.2 ppm).
There are no natural sources for chlorobenzene and most releases result from its use as a solvent 
(6). The substance is delivered into the environment mainly with exhaust air and waste water 
from production plants, processing industries and from its use as a solvent. In the atmosphere, 
chlorobenzene is anticipated to degrade slowly by free radical oxidation. Due to its high 
volatility, chlorobenzene is expected to evaporate rapidly into air when released to surface 
water, but when released to the ground it has been assumed to first bind to the soil and then 
migrate slowly to the ground water (6). In January 1987, there was an accidental release of 
approximately 450 tons of monochlorobenzene to the Baltic Sea outside Kotka, Finland (39). 
Because the sea was calm and covered with ice, it was believed that most o f the chlorobenzene 
sank to the bottom of the sea. The environmental consequences o f this release are not known.
Chlorobenzene is resistant to biodegradation as well as to chemical and physical degeneration 
(6, 32). In accordance with its relatively high lipid solubility, it has been shown to bioaccumu- 
late in, for example, fish and algae (6). In 1978 it was estimated that almost a total of 80,000 
tons of chlorobenzene were released to the atmosphere each year in the United States (32). 
Apart from an occupational exposure, humans may be exposed to chlorobenzene from drinking 
water, food, ambient air and consumers’ products.
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Based on various national surveys, the U.S. EPA has estimated the concentrations of 
chlorobenzene to be less than 1-5 pg/1 in groundwater, and less than 1 jug/1 in surface water 
(32). The magnitude o f the potential dietary intake of chlorobenzene was not estimated since 
the available data were considered insufficient (32). The median concentration of chloroben­
zene in ambient air o f urban and suburban areas has been calculated at 1.5 (ig/m3 (32). Various 
measurements performed in Germany and The Netherlands showed that the average outdoor 
air levels o f chlorobenzene varied between 0.3 and 1.5 fig/m3 (19).
Like other volatile halogenated hydrocarbons, chlorobenzene may very well be present in the 
indoor air of, for example, household settings in amounts exceeding those o f the ambient air. 
When the indoor air concentrations of chlorobenzene were measured in the Bavarian city, Hof, 
Germany, these were found to vary between 0.1 and 4 |4g/m3, with a geometric mean of 
0.5 |Jg/m3 (19). Somewhat higher indoor air concentrations were found in various cities in the 
USA, ranging between not detectable and 72.2 fig/m3, with an average o f 16.5 (Jg/m3 (19).
Chlorobenzene may be formed during the biotransformation o f other compounds. It has, for 
example, been shown that chlorobenzene is a major metabolite o f hexachlorocyclohexane, 
better known as the insecticide Lindane, at least when Lindane is incubated with rat liver 
microsomes under anaerobic conditions (14).
To summarize, although chlorobenzene may be present in ambient air, the levels are generally 
considerably lower than those that can be found in industries manufacturing or processing 
chlorobenzene.
3.3 Analytical M ethods for Air Monitoring
NIOSH manual of analytical methods (69) describes a standardized method for sampling and 
analysis for chlorobenzene in ambient air. The method was revised in 1987 (69b). First a 
known volume of air is drawn through a charcoal tube to trap the organic vapors present. Then 
the charcoal in the tube is transferred to a stoppered sample container where the amount of 
chlorobenzene adsorbed to the charcoal is eluated with carbon disulfide. An aliquot of the 
desorbed sample is then injected into a gas chromatograph with a flame ionization detector 
(GC-FID). The amount of chlorobenzene present in the sample is determined by measuring 
and comparing the areas under the resulting peaks from the sample and those obtained from 
the injection of standards.
Sampling can be done either actively with adsorption tubes or passively through personal air 
sampling using passive diffusion techniques. It seems as if most investigators have preferred 
personal air sampling using a passive organic solvent sampler in the breathing zone, when 
they measured the occupational exposure to chlorobenzene (56, 71, 96). Using personal air 
sampling and GC analysis, the detection limit has been reported to be 0.05 ppm (0.23 mg/m3) 
for an exposure time of 8 hr in an industrial setting (56). Alternatives to the GC-FID technique 
have also been used for the analysis of ambient air levels of chlorobenzene; for example, high 
pressure liquid chromatography (96). To confirm the identity o f the compound, GC can be 
combined with mass spectrometry (71).
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A similar technique is used when the amount o f chlorobenzene is determined in water samples. 
The procedure used is the so-called purge-and-trap gas chromatographic procedure, a standard 
method for the determination o f volatile organohalides in drinking water (6). An inert gas is 
bubbled through the sample so that chlorobenzene is trapped on an adsorbent material. The 
adsorbent is then heated to drive chlorobenzene onto a GC column.
3.4 P resen t O ccupational S tandards
In 1989, ACGIH adopted a TLV-TWA of 10 ppm (46 mg/m3) for the occupational exposure 
to chlorobenzene in the United States (2). Their previous limit o f 75 ppm (345 mg/m3) was 
considered low enough to prevent narcotic effects or chronic poisoning (92). The suggested 
reduction from 75 to 10 ppm was done to prevent chlorobenzene-induced injuries to the liver 
and kidneys. The current OSHA permissible exposure limit is 75 ppm (71b).
The maximum concentration value (the so-called MAK value) o f chlorobenzene allowed 
in occupational settings in the Federal Republic o f Germany was established as 50 ppm 
(230 mg/m3) in 1971 (26); a concentration that still seemed valid in 1990 (56). At present, there 
are no standards or recommendations for occupational exposure to monochlorobenzene in 
Sweden (88).
Maximum recommended concentrations in workplace air in the USSR and Czechoslovakia 




Chlorobenzene is absorbed via respiratory and dermal routes, but no quantitative experimental 
data was found on the pulmonary or dermal absorption rates. It is generally assumed that 
chlorobenzene is not readily absorbed through the skin, but prolonged contact can result in 
mild chemical bums (2, 91).
Consequently, in occupational settings inhalation o f vapors is regarded as the major route of 
exposure for chlorobenzene, dermal contact being o f minor importance. An unpublished 
simulation study by Droz, cited by ACGIH (2), suggests that the pulmonary retention at 
steady-state is about 60 percent.
4.2 Distribution
Various experimental studies have shown that, after being absorbed, chlorobenzene is dis­
tributed rapidly to various organs.
Animals: The toxicokinetics of inhaled chlorobenzene has been studied by Sullivan and 
coworkers and reported in two different papers (86, 87). The study has also been briefly 
reviewed in a short notice (4). Male Sprague-Dawley rats were exposed to 14C-chlorobenzene 
(uniformly labelled) at 100, 400 or 700 ppm (460, 1,840 or 3,220 mg/m3) for 8 hr/day; either 
one day only or for five consecutive days. Each group consisted o f six animals. Immediately 
after the last exposure, three rats from each group were sacrificed for determination of 
chlorobenzene-associated radioactivity in liver, kidneys, lungs, adipose tissue and blood. The 
remaining rats were kept in metabolism cages for 48 hr before they were sacrificed. The 
vapor concentrations of chlorobenzene were monitored with an infrared gas analyzer at 9.25 
pm.
Adipose tissue was found to accumulate the largest amounts o f radioactivity. The percentage 
of chlorobenzene-associated radioactivity in fat, presumably representing unchanged sub­
stance, was found to increase at higher exposure levels. In the other tissues investigated, the 
14C-levels w'ere increased in proportion to the exposure concentration; liver and kidneys being 
the dominant organs. Lung and blood contained 25-50%  and 10-30% , respectively, o f  
the amounts found in the liver. When the exposure concentration was increased from 100 
to 400 ppm (from 460 to 1,840 mg/m3), there was an increase o f over ten-fold o f the exhaled 
amount of radioactivity, presumably representing unchanged substance. A further increase to 
700 ppm (3,220 mg/m3) caused another seven-fold increase o f the exhaled amounts. The 
data showed that the metabolic clearance from the blood became saturated at an exposure
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concentration of 400 ppm for 8 hr. At this exposure, there was also a reduced predominance 
of the excreted amount of mercapturic acid (the only urinary metabolite investigated) in 
relation to the total amount of radioactivity excreted in the urine. Consequently, the observed 
dose-related changes in various pharmacokinetic parameters in rats suggests that the metabolic 
elimination of chlorobenzene becomes saturated at high dose levels.
Maximum liver concentrations of chlorobenzene-associated radioactivity in male Sprague- 
Dawley rats given 14C-chlorobenzene as a single i.p. injection was seen 24 hr after the 
administration (22). The radioactivity represented both the parent compound and its metabo­
lites.
The distribution and fate of nonvolatile radioactivity from uniformly labelled 14C-chlorobenzene 
has also been studied in female C57BL mice, using whole-body autoradiography (16). Six 
mice were given a single i.v. injection of the labelled compound diluted with unlabelled 
substance (1.2 mg/kg b.wt.; 7 (jCi in DMSO). The survival times were 1 and 5 min; 1, 4, and 
24 hr; and 4 days, respectively. Two other mice were injected i.p. and killed after 4 and 24 hr, 
respectively. Whole-body autoradiograms from heated tissue sections showed a selective 
localization of nonvolatile metabolites in the mucosa of the entire respiratory system 1 min 
after an i.v. injection. The labelling of the mucosa of the respiratory tract was persistent and 
still present 4 days after the injection. Microautoradiography showed that the chlorobenzene- 
associated radioactivity was bound to the epithelium of the tracheo-bronchial mucosa. Uptake 
of nonvolatile radioactivity was also observed in other tissues 1 and 5 min after the i.v. 
injection, although not to the same extent as in the respiratory tract. Relatively high amounts 
of nonvolatile metabolites of chlorobenzene were also observed in the liver, the cortex of the 
kidney, the mucosa of the tongue, cheeks and esophagus and in the inner zone of the adrenal 
cortex.
Humans: Due to its high lipid solubility, chlorobenzene can be anticipated to accumulate in 
human fat, and possibly in milk. However, none of the recognized studies on chlorobenzene 
levels in human fat and breast milk samples from the general population included 
monochlorobenzene among the various isomers measured (23, 47, 64). The chlorobenzenes 
analyzed in the monitoring programs generally included various isomers o f dichlorinated and 
trichlorinated benzenes and pentachlorobenzene and hexachlorobenzene.
4.3 Biotransform ation
Like other monosubstituted halogenated benzenes, chlorobenzene is oxidized by the micro­
somal cytochrome P-450 system to reactive epoxide intermediates (also known as arene 
oxides). These have not actually been isolated and identified, but their presence has been 
deduced from the various metabolic end-products of chlorobenzene that have been isolated 
and identified, both in vitro and in vivo. Covalent binding of chlorobenzene-related epoxides 
to various tissue constituents has provided a convenient explanation for the cytotoxic effects 
observed in various organs after the administration of the otherwise unreactive chlorobenzene 
(for further discussion see p. 18). The epoxides are converted either nonenzymatically to 
various chlorophenols or enzymatically to the corresponding glutathione (GSH) conjugates
10
and dihydrodiol derivatives. The GSH conjugates are either eliminated as such, or transformed 
to even more water-soluble products and excreted in the urine as mercapturic acids. The 
dihydrodiol derivatives are converted to catechols and excreted as such in the urine.
Experimental animals and cultured cells: It has been known for a long time that chloroben- 
zene and other halogenobenzenes are transformed in the body into phenols and mercapturic 
acids. As early as 1950, Spencer and Williams (84) were able to show that Chinchilla rabbits 
(sex was not specified) given a single oral dose o f chlorobenzene (150 mg/kg b.wt.) excreted 
52 percent o f the given dose as oxygen conjugates (25 percent as glucuronides and 27 percent 
as etheral sulphates) and 20 percent as sulphur conjugates (mercapturic acids). The figures 
were based on excretion data from three rabbits. Subsequently performed experiments on 
rabbits showed that the first step in the metabolism of chlorobenzene was the oxidation of the 
aromatic nucleus, resulting in an epoxide as an intermediate precursor for the further metabo­
lism (see, e.g., reference 59).
Lindsay Smith et al. (59) gave an emulsion of 14C-chlorobenzene in Cremophore E.L. and 
physiological saline orally to two female Dutch rabbits (0.5 g x 2/day for 4 days). During the 
four days of dosing and the three following days, urine and feces were collected separately. 
The amounts excreted via feces were negligible. The major metabolites identified in the urine 
were p-chlorophenylmercapturic acid and conjugates o f 4-chlorocatechol (i.e., etheral sul­
phates). Other urinary metabolites identified were quinol, 3-chlorocatechol and ortho- and 
m-chl orophenylmercapturate.
The hepatic metabolism of chlorobenzene in vitro was studied extensively in various ex­
perimental systems by Selander and coworkers (81). They employed both perfused rat livers 
from male Sprague-Dawley rats and various cell-free hepatic preparations: postmitochondrial 
supernatants, microsomes and reconstituted soluble hemoprotein systems. The experiments 
were conducted using 14C-labelled chlorobenzene diluted with appropriate amounts o f un­
labelled substance, with and without the addition of various inducers and inhibitors of 
cytochrome P448/P450 monooxygenases. The formation of chlorophenols and dihydrodiols 
was determined using HPLC-technique. Whereas the pretreatment o f rats with 3-methyl- 
cholantrene, a cytochrome P448-inducer, resulted in a significant and selective increase in the 
formation of ortho-chlorophenol in all hepatic systems employed, a similar pretreatment with 
the cytochrome P450-inducer phenobarbital only resulted in a moderate increase o f ortho- and 
para-chlorophenol. Various inhibitors o f the cytochrome P450 and/or P448 systems such as 
carbon monoxide, metyrapone, SKF-525A and 7,8-benzoflavone, affected the biotransfor­
mation of chlorobenzene in various ways. Whereas the formation of ortho-, meta- and 
para-chlorophenols was inhibited by carbon monoxide and metyrapone, the addition of 
SKF-525A and 7,8-benzoflavone was found to inhibit the formation o f ortho- and p-chloro- 
phenol to a greater extent than that of m-chlorophenol. The addition of high concentrations of 
glutathione reduced the formation of all three chlorophenols.
Consequently, once absorbed, one of the first steps in the metabolic conversion of chloroben­
zene is the formation o f a mixture o f chlorophenols. The cytochrome P450/P448 mono­
oxygenase system is involved in the formation of ortho- and para-chlorophenol. It is during
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these reactions, two different reactive epoxides are formed as intermediate species. One 
o f the epoxides, chlorobenzene-3,4-epoxide, rearranged to p-chlorophenol. The other 
chlorobenzene-related epoxide, chlorobenzene-2,3-epoxide, isomerize to o-chlorophenol 
(50). The third chlorophenol that is formed during the metabolic biotransformation of 
chlorobenzene, m-chlorophenol, is probably formed by direct oxygen insertion in the parent 
compound (55, 81).
In a study where the in vitro hepatic microsomal formation o f halophenols from chlorobenzene 
and bromobenzene was investigated in both human and mouse liver microsomes (50), 
important differences were observed between the metabolic pathways suggesting that humans 
may be more susceptible than mice to halobenzene-induced hepatotoxicity. Mouse liver 
microsomes were prepared from untreated male B6C3F1 mice (livers from 35 mice were 
pooled). Human liver microsomes were made from transplants obtained from three different 
donors who suffered acute head injuries in accidents. Mixtures containing microsomal proteins 
and various co-factors were incubated with either chlorobenzene or bromobenzene. The 
formation of halophenols was studied using a selective HPLC method with electrochemical 
detection (HPLC/ECD-technique).
The metabolism of chlorobenzene to ortho- and p-chlorophenol followed the same pattern as 
that of bromobenzene, both in human and mouse liver microsomes, indicating that both 
compounds were metabolized by the same cytochrome P450/P448-isozymes. Microsomes 
from the mouse liver contained approximately five times more cytochrome P450 than those 
taken from the livers of the three donors, but the production of p-halophenols was only two 
times greater in the mouse liver enzymes. When the production of p-halophenols (i.e., the 
metabolic pathway that has been associated with the hepatotoxicity of chlorobenzene and 
bromobenzene) was expressed relative to the cytochrome P450 content (i.e., nmol of 
halophenol produced/min/nmol o f cytochrome P450), the human liver microsomes were 
twice as efficient as the mouse liver microsomes. Moreover, in comparison to the mouse 
liver microsomes, human cytochrome P450-isozym es produced less o f the nonhepatotoxic 
o-halophenols. Whereas the ratio of para- to ortho-halophenol production was 1.3 for 
bromobenzene and 1.4 for chlorobenzene in the mouse microsomes, the average ratio was 4.8 
for both compounds in the human microsomes. The human liver microsomes also had a slightly 
greater affinity for chlorobenzene and bromobenzene than the mouse microsomes. Taken 
together, these in vitro results indicate that the main metabolic pathway of chlorobenzene in 
human liver microsomes is through the hepatotoxic 3,4-epoxide pathway.
Studies on the metabolism of chlorobenzene have mainly been restricted to the liver. However, 
experiments performed in vitro with tissue slices prepared from pieces o f nasal mucosa, lung, 
and liver taken from female C57BL mice, showed that chlorobenzene can also be transformed 
to nonextractable metabolites in extrahepatic organs (16). In these experiments, tissue slices 
were incubated with 14C-labelled chlorobenzene (5 |iM; 0.3 juCi) in a phosphate buffer 
containing glucose, and in the presence o f oxygen, for 15, 30 or 60 min. Incubation 
mixtures with tissue slices heated for 10 min were used as controls. All three organs 
investigated were found to produce metabolites that could not be removed by extensive organic 
solvent treatment; nasal mucosa being the most efficient tissue. After 60 min o f incubation,
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the nasal mucosa had produced approximately 0.8, the lung 0.4 and the liver 0.2 pmoles 
14C-metaboIites/mg wet weight tissue. In a second series o f experiments, the effect of various 
mixed function oxidase inhibitors on the extrahepatic metabolism o f chlorobenzene, was 
investigated using tissue slices from nasal mucosa and lung (16). The formation o f nonextract- 
able metabolites in vitro was decreased by metyrapone, piperonylbutoxide and SKF-525A, 
clearly showing that the metabolism of chlorobenzene is also cytochrome P450-dependent in 
these organs.
The major m etabolites o f  chlorobenzene in man appear to be p-chlorophenol and 
4-chlorocatechol (2). These are eliminated in the urine as sulphate and glucuronide conjugates 
in the urine. Apparently, the metabolic pathways in man differ somewhat from those in rabbits 
and other experimental animals. Para-chlorophenol is, for example, only a minor urinary 
metabolite of rabbits (12), and a major excretion product in rabbit urine, p-chlorophenyl 
mercapturic acid, is excreted only in min amounts in human urine.
The proposed metabolic pathways for chlorobenzene are shown in Figure 1 (p. 14). The scheme 
is based on in vitro findings and various experimental toxicokinetic data (2 ,1 1 ,1 6 ,5 0 ,5 5 ,5 9 ,  
81, 84, 86,87), as well as human urinary excretion data (56, 7 0 ,7 1 ,9 6 ). The latter studies are 
discussed in more detail in the sections reviewing data on the elimination pattern and biological 
exposure indicators.
4.4 Elimination
There are three potential routes o f elimination for inhaled or ingested chlorobenzene, via the 
expired air, via the urine, and via feces. Although the eliminated amount o f unchanged 
chlorobenzene in the expired air may be as high as 60% depending on the exposure conditions 
and species involved, urinary excretion o f various chlorobenzene-associated metabolites is no 
doubt the dominant route of elimination for chlorobenzene. Excretion o f unchanged substance 
via urine or feces is consequently unimportant. At the dose levels humans normally are exposed 
to, most of the chlorobenzene absorbed is believed to be metabolized and then excreted in the 
urine, predominantly as free and conjugated forms of 4-chlorocatechol and chlorophenols.
Animals: Experiments on three Chinchilla doe rabbits given a single oral dose of 500 mg 
chlorobenzene/kg b.wt., showed that the eliminated amount o f unchanged chlorobenzene in 
the expired air was as high as 24-32% during the first 30 hr following the administration of 
the compound (11). Another experiment on Chinchilla rabbits given a single oral dose o f 
150 mg chlorobenzene/kg b.wt. (84), showed that 72 percent o f the given dose was eliminated 
as various conjugates in the urine within two days after the administration.
Although the route of administration seems o f minor importance for the elimination pattern 
of chlorobenzene, dose levels and dosing schedule may have some influence.
In the previously mentioned pharmacokinetic study of inhaled 14C-chlorobenzene (86 ,87), it 
was shown that multiple exposures o f rats at doses saturating the metabolic pathways, versus 
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higher tissue levels of radioactivity (notably in adipose tissue), a lowered total excretion of 
chlorobenzene-associated radioactivity, a lesser percentage o f the total amount excreted 
through respiration and a change in the rate o f respiratory excretion. Consequently, rats 
exposed to 100 ppm (460 mg/m3) for 8 hr, excreted only 5% o f the total dose via exhalation 
and 95 % in the urine. Repeated exposure to 700 ppm (3,220 mg/m3), 8 hr/day for 4 -5  days, 
resulted in exhalation o f 32% of the total dose, the urinary excretion being 68%.
In a study of the liver toxicity of chlorobenzene in male Sprague-Dawley rats given the 
compound as a single i.p. injection (22), it was found that the fraction o f the total dose excreted 
in the urine within 24 hr decreased as the dosage o f chlorobenzene increased. At the lowest 
dose tested, 2.0 mmol/kg b.wt. (225 mg/kg), 59% of the total dose was excreted in the urine, 
but at the highest dose, 14.7 mmol/kg (1,655 mg/kg), the corresponding figure was only 19% 
(all of the excreted products represented metabolites).
In an investigation on the potential differences between various species with regard to the 
elimination pattern of chlorobenzene, rats, mice, and rabbits were given an i.p. injection of
0.5, 1 or 2 mmol (i.e., 56, 112 or 225 mg) monochlorobenzene/kg b.wt. (70). An additional 
group of rats was also given chlorobenzene orally at a dose o f 0.3 mmol/kg b.wt. (34 mg/kg); 
the substance was administered diluted in polyethylene glycol. No information was given on 
the number or strains of the mice and rabbits, but the elimination pattern in the rats was 
established from data obtained from four females o f the Wistar strain. Also included in the 
study was one male volunteer given chlorobenzene orally (3 x 0.3 mmol/kg b.wt.) and two 
occupationally exposed workers with estimated inhalation exposures o f 0.84 ppm x 415 min 
and 0.5 ppm x 228 min, respectively. Urinary samples were collected periodically and the 
amounts of two different chlorobenzene associated metabolites, p-chlorophenylmercapturic 
acid and 4-chlorocatechol were measured using HPLC. There was a dose-related increase of 
the excreted amounts o f both metabolites in the urine from the rats, mice, and rabbits. However, 
whereas the mercapturic acid derivative was the dominant excretion product in the urine of 
the animals, it was only a fraction o f the amount o f 4-chlorocatechol collected in the urine 
from the chlorobenzene exposed humans.
In another study (55), chlorobenzene was diluted in com oil and given to ten male Wistar rats 
as a single i.p. injection (500 mg/kg b.wt.). Four rats were pretreated with 80 mg phenobarbi- 
tal/kg b.wt., 54 hr before the chlorobenzene injection. Twenty-four-hr urinary samples were 
collected over a period o f seven days and analyzed for the presence o f p-chlorophenylmercap- 
turic acid, various chlorophenols and guanine adducts using different chromatographic tech­
niques. The major urinary metabolite identified was p-chlorophenylmercapturic acid, the total 
amount excreted being 13.5 mg after six days. Most o f the p-chlorophenylmercapturic acid 
was excreted during the first 24 hr (65% of the total amount). The pretreatment with 
phenobarbital did not significantly affect the elimination pattern of this particular metabolite. 
The excretion o f para-, meta- and ortho-chlorophenol was significantly lower. The total 
amount of free chlorophenols was 1.1 mg after 6 days. The corresponding figure for free and 
conjugated chlorophenols was 2.55 mg. The ratio o f free para- to meta- to ortho-chlorophenols 
was 4:3:1 and that for free and conjugated forms 3:2.3:1. Pretreatment with phenobarbital was 
found to have a significant effect on the elimination pattern of the various chlorophenols. The
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excretion of para- and meta-chlorophenol was twice as high in rats given phénobarbital before 
chlorobenzene as compared to the amounts excreted by those given chlorobenzene alone. In 
the case of o-chlorophenol, there was a fourfold increase of the excreted amount in the 
phenobarbital-induced rats. A DNA-adduct, probably identical with N7-phenylguanine, was 
also present in the urine 1 and 2 days after the injection, and between day 4 and 6  after the 
administration. The total amount of adduct excreted in the urine was low (29 |ig after 6  days) 
and was not affected by the pretreatment with phénobarbital.
Humans: As indicated above, the elimination pattern of chlorobenzene-associated metabolites 
in humans appears to differ from that observed in experimental animals (70). It was shown in a 
Japanese field study (96), for example, that 11 persons occupationally exposed to 1.7-5. 8  ppm 
(7.8-26.7 mg/m3) chlorobenzene for 8  to 11 hr, excreted more than 75 % of the urinary metabolites 
as 4-chlorocatechol, and more than 20% as various chlorophenols (the dominant isomer 
being p-chlorophenol). A main urinary metabolite of chlorobenzene in rats and rabbits, 
4-chlorophenylmercapturic acid, was present only in insignificant amounts (0.4% of the total 
amount of the chlorobenzene-related urinary metabolites). Chlorophenylmethylsulfides were 
not detected at all. A similar study from Belgium on 44 chlorobenzene-exposed workers (56) 
showed that more than 80% of the excreted 4-chlorocatechol and p-chlorophenol in the urine 
was eliminated within 16 hr after the end of exposure (i.e., end of shift). Both studies are 
described in more detail under the section “Biological Exposure Indicators.”
In a controlled exposure chamber study (71), five male volunteers were exposed for 7 hr to 
either 12 or 60 ppm (55 or 276 mg/m3) monochlorobenzene. Elimination curves for major 
urinary metabolites were calculated using pharmacokinetic models. In the calculations, the 
exposure was standardized to 1 ppm chlorobenzene and it was assumed that the absorption 
rate for chlorobenzene in the lung was 100%. Two-compartment models gave the following 
estimated half-lives for 4-chlorocatechol: 2.2 hr (phase I; fast) and 17.3 hr (phase II; slow). 
The corresponding half-lives for p-chlorophenol were 3.0 and 12 hr, respectively. When the 
data were fitted to a one-compartment model, the biological half-lives of 4-chlorocatechol and 
p-chlorophenol were estimated to be 2.9 and 7 hr, respectively.
4.5 Biological E xposure Indicators
Measurements of chlorobenzene in blood, and possibly also exhaled air, can be used for 
monitoring purposes (2,71). However, the best biological exposure indicator for chlorobenzene in 
humans is, as previously discussed, the presence of 4-chlorocatechol and p-chlorophenol in 
the urine.
The urinary concentrations of 4-chlorocatechol and p-chlorophenol are determined by HPLC 
(56,70,96). Various protocols have been used, but one way is to treat the urine with perchloric 
acid at 95°C, and then extract the metabolites with diisopropyl ether. The ether fraction 
is evaporated and the residue is dissolved in acetonitrile and water. An aliquot of this 
fraction is then separated on a column packed with for example chrompack C18, using 
acetonitrile/water/hexasulphonic acid as the mobile phase (56). The detection limit using the 
described procedure, a flow rate of 0 . 8  ml/min and peak detection at 282 nm, has been reported
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to 0.2 mg/ml (56). Recently, Ogata et al. (71) described a slightly modified procedure 
eliminating the ether extraction step. In the revised protocol, the urinary samples are first 
treated with various enzymes, and then the enzymatic hydrolysates are applied directly on a 
column for HPLC.
One of the first studies showing a good correlation between air concentrations of chloroben- 
zene and urinary concentrations of metabolites was the above-mentioned field study by 
Yoshida et al. (96). The chlorobenzene concentrations were measured in the air of two different 
chemical factories using personal air sampling. The total number of subjects was eleven, and 
the exposure time per shift varied between 8  and 1 1 hr. The estimated air concentrations ranged 
between 1.7 and 5.8 ppm, with a geometric mean of 3.15 ppm (14.5 mg/m3). The previously 
mentioned field study from Belgium (56), involving 44 male workers in a diphenylmethane-
4 -4 ’diisocyanate-producing plant, confirmed the good correlation between air concentrations 
of chlorobenzene and urinary levels of 4-chlorocatechol and 4-chlorophenol at the end of shift. 
The time-weighted average exposure values in the latter study were log-normally distributed 
and varied from 0.05 to 106 ppm, with a median value of 1.2 ppm (5.5 mg/m3). From 
extrapolations performed on the data, it was calculated that 8  hr exposure to 50 ppm 
chlorobenzene (230 mg/m3), without any simultaneous skin contact to the compound, would 
give an average urinary concentration of 33 mg total chlorocatechol/g creatinine and 9 mg 
total p-chlorophenol/g creatinine at the end of a working day.
ACGIH recently recommended that measurements of the total amounts of 4-chlorocatechol 
and p-chlorophenol (i.e., both free and conjugated forms) should be used for monitoring 
occupational exposure (2). Based on data from studies cited above (70, 71, 96) and an 
unpublished simulation study by Droz (cited in reference 2), ACGIH recommended the 
following biological threshold limits (biological exposure indices; BEIs): 150 mg total
4-chlorocatechol/g of creatinine (= 116 mmol/mol of creatinine) and 25 mg total 
p-chlorophenol/g creatinine (= 2 2  mmol/mol creatinine) at the end of shift.
Even if 4-chlorocatechol and p-chlorophenol are assumed to be absent in the urine taken from 
a general population, it may be worthwhile to note that the presence of them is not exclusively 
linked to an occupational exposure to monochlorobenzene. Both metabolites may, for example, 
also be found in the urine from persons exposed to dichlorobenzenes or p-chlorophenol (2 ).
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5 GENERAL TOXICITY
In this section, information from various types of general toxicity tests (i.e., tests for acute, 
subchronic, and chronic toxicity) on experimental animals has been gathered together with the 
scarce amount of data available regarding human chlorobenzene exposure. Information from 
various types of experimental tests measuring specific toxicological endpoints such as im- 
munotoxicity, genotoxicity, carcinogenicity, reproductive toxicity and teratogenicity are 
treated separately (pp. 38-54). Moreover, following the general outline of traditional NIOH 
criteria documents, information on specific organ effects has been gathered in a separate 
section, starting on p. 28. The section “General Toxicity” begins with a discussion on 
toxicological mechanisms.
5.1 S uggested  Toxicological M echanism s
As previously discussed, chlorobenzene undergoes oxidative metabolic bioactivation to form 
epoxides. It is generally assumed that the toxicity of chlorobenzene is mediated by covalent 
binding of reactive metabolic intermediates to critical cell structures. However, the exact 
molecular mechanisms of action behind the various toxic effects of chlorobenzene remain 
unknown. Different mechanisms may be involved in the various organs that are associated 
with chlorobenzene-induced toxicity.
The reactive electrophilic metabolites formed in the liver are detoxified mainly by conjugation 
with reduced glutathione, GSH. Liver damage following exposure to chlorobenzene and other 
monosubstituted halogenated aromatic monocyclics has therefore been attributed to the 
depletion of hepatic glutathione, leaving the reactive metabolites free to bind covalently to 
proteins and other cellular macro-molecules (17,76). It has been suggested that the hepatotoxic 
effects of chlorobenzene are mainly mediated by the 3,4-epoxide that subsequently rearranges 
to p-chlorophenol (50, 54). Since the hepatotoxic effects of chlorobenzene are mediated by 
one or several reactive metabolites, it should be possible to modulate the toxicity by affecting 
the enzyme systems involved. Consequently, experiments in rats have shown that the liver- 
damaging effect of chlorobenzene is potentiated when the cytochrome P450 enzyme system 
is induced with phenobarbital (17).
Impairment of the main detoxifying enzyme system, i.e., mainly the GSH conjugation 
pathway, could possibly also affect the hepatotoxicity of chlorobenzene. If the detoxification 
system is handicapped (e.g., by administration of large doses of chlorobenzene) the amount 
of reactive metabolites available for toxic insults would then theoretically be increased. Initial 
depletion of hepatic glutathione levels has been shown in both rats (22, 95) and mice (83) 
given chlorobenzene intraperitoneally. However, this seems to be a transient phenomenon 
without any obvious dose-response relationship (22,83). It may also be pointed out that since
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chlorobenzene appears to lower the cytochrome P450 levels, at least in the livers of rodents 
given the compound orally or intraperitoneally (9, 22), exposure to chlorobenzene seems 
associated with a lowered capacity of both bioactivating and detoxifying enzyme systems. The 
cited studies are described in more detail on pp. 29-32.
Koizumi et al. (54) showed that the bromobenzene-induced hepatotoxicity in male Wistar rats 
could be modified if chlorobenzene was given simultaneously. Groups of rats ( 6  animals/group) 
were given an i.p. injection of bromobenzene, alone ( 2  mmole/kg b.wt) or in combination with 
chlorobenzene (4 mmole/kg). The rats were killed after 12, 24, 48 or 72 hr. Hepatotoxicity 
was assessed both biochemically and histopathologically. The injection of a mixture of 
bromobenzene and chlorobenzene initially suppressed the hepatotoxic effects of bromoben­
zene alone (24 hr after the injection). However, at a later stage there was a dramatic potentiation 
of the toxicity, the maximum response being observed 48 hr after the injection. This was true 
both with regard to the bromobenzene-induced ALAT elevation and the centrilobular necrosis. 
Whereas the suppression in the early phase was believed to be a result of metabolic inhibition 
of the 3,4-epoxidation pathway, the subsequent potentiation was most likely a result of a 
delayed recovery in the glutathione levels.
The causal role of protein binding to the chlorobenzene-induced hepatotoxicity has been 
questioned. In the previously mentioned study of male Sprague-Dawley rats given a single
i.p. injection of chlorobenzene (2 2 ), little correlation was found between the histopathological 
and functional damages of the liver and the metabolism of the substance. A poor correlation 
was also found between the extent of liver damage and the degree of protein binding. The dose 
that produced the most extensive liver necrosis (14.7 mmol/kg b.wt., i.e., 1,655 mg/kg) gave 
the same degree of protein binding as the dose producing only a minimal necrosis 
(4.9 mmol/kg; 552 mg/kg).
Oxidative stress is one alternative mechanism of action that has been proposed to explain 
the hepatotoxic effects of chlorobenzene and other aryl halides (21). Evidence for this 
alternative, or complementary, mechanism of action was obtained from experiments on 
cultured rat hepatocytes. In this particular in vitro system it was shown that the toxicity 
of chlorobenzene, bromobenzene and iodobenzene could be manipulated in ways that 
modified the sensitivity of the cells to oxidative stress. Primary cultures of hepatocytes 
were prepared from livers taken from Sprague-Dawley rats pretreated with phenobarbital 
for three days (21). Chlorobenzene and the two other aryl halides were diluted in DMSO 
and added to the cultures for 2 hr of exposure, with and without addition of l,3-bis(2- 
chloroethyl)-l-nitrosourea (BCNU). The latter compound inhibits glutathione reductase, 
an enzyme that plays an important role in the glutathione redox cycle and is responsible 
for the reduction of GSSG to GSH. The concentrations of chlorobenzene varied between 
0.25 and 2 mM. Cell viability was determined after 4 hr. The cultured hepatocytes were 
not as sensitive to the toxicity of chlorobenzene as that of bromobenzene or iodobenzene. 
However, all compounds induced the same type of effects, although at different concentra­
tions. At 1 mM of chlorobenzene alone, there was a 30% cell killing, but when BCNU 
was added to the cultures, the cell killing increased to 90%. BCNU was without toxic 
effects of its own. The enhanced cell killing in the presence of BCNU could be completely
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prevented by SKF-525A, an inhibitor of the mixed function oxidase system. The changes of 
cell killing in the presence of BCNU occurred without parallel changes in the metabolism or 
covalent binding of [1 4 C] bromobenzene (not investigated parameters in the case of 
chlorobenzene and iodobenzene).
It has also been suggested that the hepatotoxic effects of chlorobenzene are mediated through 
an alpha-adrenergic system (83). When phentolamine, an alpha-adrenergic antagonist, was 
given to male B6C3F1 mice after an i.p. injection of chlorobenzene, the chlorobenzene - 
induced hepatotoxicity was significantly reduced.
The kidneys are also main targets for chlorobenzene-induced toxicity (75). However, here it 
is the 2,3-epoxide, subsequently rearranging to o-chlorophenol, which has been suggested to 
be the responsible reactive species (50, 51). Pretreatment of mice and rats with piperonyl 
butoxide, an inhibitor of microsomal enzymes, blocks the renal toxicity of chlorobenzene. 
However, in contrast to the liver, pretreatment with phenobarbital did not enhance the kidney 
toxicity of chlorobenzene to a significant extent (75).
Covalent binding of chlorobenzene-associated metabolites has not only been observed in 
proteins, but also to RNA and DNA taken from various organs of mice and rats given 
1 4 C-labelled chlorobenzene (20,40,73). The reported binding of 1 4 C-chlorobenzene- 
associated radioactivity to nucleic acids should be interpreted with some cautiousness, 
because of the conceivable problem of protein contamination. Reid (75), for example, 
stated, without giving any figures, that nucleic acids isolated from liver and kidneys of 
mice and rats given 1 4 C-chlorobenzene did not contain any “significant amounts” of 
covalently bound radioactivity. To examine the reported ability of chlorobenzene to 
interact directly with DNA in more detail is of great interest, especially when one 
considers that chlorobenzene has been reported genotoxic in some short-term tests for 
mutagenicity and/or genotoxicity (see pp. 39-47).
The third major target for chlorobenzene-induced toxicity is the central nervous system. 
No studies were available with regard to the mechanism of action of the narcotic and CNS 
depressant effects of chlorobenzene. This is not surprising when one considers that, so 
far, nobody knows exactly how conventional inhalational general anesthetics act on a 
molecular basis. Several theories have been proposed. One theory is that general anes­
thetics act by inducing reversible binding directly to a particularly sensitive protein in the 
neuronal membrane, thereby inhibiting its normal function (37), possibly by competing 
with endogenous ligands (38). The current hypothesis seems to be that general anesthesia 
at a molecular level, either follow from changes in lipid thermotropic behavior or 
malfunction of neuronal proteins, or a combination of both processes (83). Since inhala­
tion anesthetics have diverse structures and act by forming reversible bonds to the critical 
structure, possibly of Van der Waals type rather than irreversible covalent-ionic bonds 
(83), it seems likely that it is chlorobenzene itself that induces the CNS-depressant effects. 
Additional support for this assumption comes from the fact that the intact compound has 
higher lipophilicity than any of the metabolites formed. High lipophilicity seems to be a 
prerequisite for CNS-depressant agents.
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To summarize, although the different toxic effects observed after administration o f chloroben- 
zene usually are induced by one or more o f the various metabolites formed, it cannot be 
excluded that the compound itself also may produce adverse effects, especially in the CNS. 
Exactly how chlorobenzene and/or its metabolites cause the toxic effects observed is not 
known in detail—not even in the liver, the organ most thoroughly studied for chloroben- 
zene-induced toxicity. Several possible toxicological mechanisms may be involved. Conse­
quently, whereas the hepatotoxic and nephrotoxic action o f chlorobenzene most likely are due 
either directly to the covalent binding o f reactive metabolites to critical structures in the cells, 
and/or indirectly to oxidative stress, the CNS-depressant effect is probably mediated by other 
toxicological mechanisms, most likely provoked by the unmetabolized substance itself.
5.2 Acute Toxicity
The acute toxicity of chlorobenzene in experimental animals is relatively low, after oral 
administration, inhalation, and dermal exposure. Consistently observed chlorobenzene-induced 
signs of acute intoxication in various species o f experimental animals include hyperemia of 
the visible mucous membranes, increased salivation and lacrimation, initial excitation fol­
lowed by drowsiness, adynamia, ataxia, paraparesis, paraplegia, and dyspnea (i.e., mainly 
signs of disturbance o f the central nervous system). Changes observed at gross necropsy 
include hypertrophy and necrosis o f the liver and submucosal hemorrhages in the stomach. 
Histopathologically observed lesions include necrosis in the centrilobular region of the liver; 
the proximal convoluted tubules of the kidneys; and the bronchial epithelium o f the lungs and 
stomach. Death is generally a result of respiratory paralysis.
Animals: There are many published and unpublished reports on the acute toxicity o f chloro­
benzene after various routes o f administration (see Table 1). The information given in the table 
was mainly obtained from secondary sources of information. The indicated primary sources 
of information are in many cases either unpublished reports, or written in a language not 
familiar to the evaluator. It has consequently not been possible to critically examine each 
individual study, and the information may appear fragmentary with regard to details on strains, 
dose levels, methods, and observations.
Apart from the studies listed in Table 1, there are also other acute toxicity studies available in 
the literature. When the acute toxicity of chlorobenzene was examined in male and female 
F344/N rats and B6C3F1 hybrid mice (51, 68), the mice were found to be more sensitive than 
the rats toward the lethal effects of the compound. However, the acute toxicity after a single 
oral dose of chlorobenzene was also low in both species in this study. The compound was 
given by gavage, diluted in com oil at the following doses: 250, 500, 1,000, 2,000 or 
4,000 mg/kg b.wt. Each group consisted of 5 males and 5 females o f each species. The animals 
were followed for 14 days and observed daily for mortality and morbidity. The animals were 
not subjected to necropsy and there were no records on possible effects on body weight gain. 
Whereas a dose of 1,000 mg/kg b.wt. was lethal to the male mice, the rats had to be given up 
to 4,000 mg/kg before mortality became evident. Most deaths occurred within a few days after 
the administration. Clinical signs of toxicity among the rats in the two highest dose groups
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Table 1.—Summary of reported LD50 and LC50 values in various published and unpublished 











Rat n.g.*/n.g. Oral 2,910 mg/kg Irish 1962 6, 19, 26
n.g./n.g. Oral 2,390 mg/kg Varshavskaya
1967
19, 32
n.g./n.g. Oral 2,300 mg/kg Eitingon 1975 19
n g /n -g . Oral 3,400 mg/kg Vecerek et al. 
1976
6, 19 ,32









n.g./n.g. Oral 1,540 mg/kg M onsanto Co. 
1982
19
n.g./n.g. Inhalation 20,000 m g/m 3 
for 2 hr = 
LC 100
Rozenbaum  et al. 
1947
19




n.g./m ales Inhalation 13,870 m g/m 3 
for 6 hr
Bonnet et al. 
1982
19





i.p. 1,655 mg/kg 22
Mouse n.g./n.g. Oral 1,445 mg/kg Varshavskaya
1967
19,32
n.g./females Inhalation 8,822 m g/m 3 
for 6 hr
Bonnet et al. 
1979
19, 32
NM RI/males i.p. 1,355 mg/kg 66
Rabbit n.g./n.g. Oral 2,830 mg/kg Irish 1962 19, 26, 32
n.g./n.g. Oral 2,250 mg/kg Varshavskaya
1967
19,32
n.g./n.g. Dermal >2,212 mg/kg AAM RL-TR 
(USA) 1987
19




Guinea pig n.g./n.g. Oral 5,060 mg/kg Varshavskaya
1967
19, 32
Cat n.g./n.g. Inhalation 17,000 m g/m 3 
for 7 hr = lethal
Gôtzmann 1904 19
n.g. = not given in the indicated sources of information
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included transient ataxia, labored breathing, and prostration. No attempt was made to evaluate 
the approximate LD50 values.
Humans: The only information available on the acute effects o f chlorobenzene in humans is 
either based on isolated case reports of poisonings or occupational exposures. However, no 
data on actual levels o f exposures were presented in any of these reports, and in occupational 
exposures it was difficult to identify chlorobenzene as a causative agent since the workers 
were exposed to a mixture o f agents.
According to various review articles (e.g., 6 , 25,32,33, 91, 92), citing the works o f Cameron 
et al. from 1933, Reich from 1934, Rozenbaum et al. from 1947, Girard et al. from 1969, and 
Smirnova and Granik from 1970, inhalation or ingestion of chlorobenzene causes drowsiness, 
incoordination, and unconsciousness (i.e., signs deriving from CNS-depression—sedation and 
narcosis) as well as irritation of the eyes and respiratory tract. Whereas some of these reports 
are briefly described below, the work of Rozenbaum et al. from 1947, describing an industrial 
exposure situation, is described in the section discussing the chronic toxicity o f chlorobenzene 
(p. 27).
According to the toxicology update by Whillhite and Book (92), citing the paper by Cameron 
et al. [published in J Pathol Bacteriol 44 (1933) 281-296], ingestion of chlorobenzene leads 
to pallor, cyanosis, methemoglobinemia, and collapse. These symptoms occurred after a delay 
in onset by several hr. No information was given on exposure levels, etc., but according to 
Whillhite and Book (92), the human probable oral acute lethal dose o f chlorobenzene has been 
estimated at 0 .5-5 g/kg b.wt.
The case-report by Reich from 1934 [published in Samml Vergiftungsfallen 5 (1934) 
193-194], refers to a 2-year-old boy who had swallowed 5 to 10 ml o f Puran, a cleaning agent 
containing chlorobenzene. The boy did not show any immediate signs of intoxication, but after 
eating lunch 2.5 hr after the ingestion of Puran, he quickly lost consciousness and suffered 
vascular paralysis and heart failure (possibly indicating that the absorption of chlorobenzene 
from the gastrointestinal tract is facilitated by ingestion of fat). The boy recovered, but the 
odor of Puran in his breath and urine persisted for 5 to 6 days.
Another of the cited cases of acute chlorobenzene intoxication, originally reported by Girard 
et al. [published in J Med Lyon 50 (1969) 771-773], refers to a 70-year-old woman who was 
exposed to a glue containing 70 percent chlorobenzene when she was manufacturing hats. 
Early complaints included headache and irritation of the upper respiratory tract and mucosa 
of the eyes.
In the previously mentioned exposure chamber study involving five volunteers exposed to up 
to 60 ppm chlorobenzene (276 mg/m3) for 7 hr (71) it was shown that this exposure was 
associated with acute subjective symptoms such as drowsiness, headache, irritation of the eyes, 
and sore throat. There is also a recently published case report (13) describing severe liver cell 
necrosis in a 40-year-old man who had ingested 140 ml o f a solution containing 90% 
chlorobenzene in a suicide attempt. The case-report is further discussed on p. 32.
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5.3 Subchronic Toxicity
Repeated administration of chlorobenzene to experimental animals for several weeks or 
months is mainly associated with liver and kidney damage. Typical evidence for the chloroben- 
zene-induced liver toxicity observed in the subchronic toxicity studies are increased activity 
of serum liver enzymes, increased liver weight, lipid accumulation, hepatic porphyria, and 
hepatocellular necrosis. The chlorobenzene-induced nephrotoxicity is mainly manifested as 
increased kidney weights, focal coagulative degeneration, and necrosis of the proximal 
tubules. Repeated administration of relatively large doses to experimental animals is also 
associated with lesions in the thymus, spleen, bone marrow, and lungs.
Although repeat-dose toxicity studies for 14 days do not fall within the category of subchronic 
toxicity studies, this section of the document begins with such a study (previously often 
referred to as “subacute” toxicity study) for practical reasons.
Animals: Male and female F344/N rats and B6C3F1 mice were given chlorobenzene diluted 
in com oil by gavage for 14 days (51,68). Groups of 5 animals were given daily doses varying 
between 0 and 2,000 mg/kg b.wt. for the rats, and between 0 and 500 mg/kg for the mice. The 
animals were observed daily for mortality and morbidity, weighed at the beginning and the 
end of the study. They were also subjected to necropsy. The 2-week daily exposure to 1,000 
and 2,000 mg/kg b.wt. resulted in 100% mortality among the male and female rats. Most deaths 
occurred within the first few days of exposure. Clinical signs of toxicity among the rats in the 
highest dose groups included prostration and reduced response to stimuli. There were no toxic 
effects that could be related to the administration of chlorobenzene in the mice. Consequently, 
the NOEL for both male and female rats and mice in this 14-day study was found to be 
500 mg/kg b.wt./day.
In a regular subchronic toxicity study on rats and mice (51, 68), male and female F344/N and 
B6C3F1 mice were given chlorobenzene by gavage, 5 days/week, for 13 weeks in the 
following doses: 0 (com oil; vehicle), 60, 125, 250, 500 or 750 mg/kg b.wt./day. Each group 
consisted of 10 animals of each sex and species. The animals were observed daily for mortality, 
morbidity and clinical signs of toxicity. Food consumption and body weights were measured 
weekly. Urine was collected during the last week of exposure, and at the end of the study. A 
blood sample was taken from the orbital venous plexus of each surviving animal and analyzed 
for various blood parameters. Clinical biochemistry determinations were performed on blood 
samples obtained from cardiac puncture, taken at the time of sacrifice. All animals were 
subjected to a complete gross examination, and a number of organs were taken for histopatho­
logic examination.
The mortality was increased in the two highest dose groups among the rats, and in the three 
highest dose groups among the mice. There were no clinical signs of toxicity reported. The 
body weight gain appeared to be reduced in the male rats and mice, starting from 
250 mg/kg/day, and among the female rats and mice starting from 500 mg/kg/day. There were 
no consistent changes in the hematological parameters, and the only significant findings 
reported from the investigation on serum chemistry were some observations made in surviving
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female rats of the two highest dose groups: slight to moderate increases in serum alkaline 
phosphatase and serum gamma glutamyl transpeptidase. Apart from increased urine volumes 
observed in some of the high-dose animals, the urinalysis showed no abnormalities.
Liver weights were slightly increased in a dose-related manner in both male and female rats 
and mice. Histologic examination showed chlorobenzene-induced lesions in the liver, kidney, 
spleen, bone marrow and thymus of both rats and mice. In the liver there was a dose-dependent 
centrilobular hepatocellular degeneration and necrosis (LOEL: 250 mg/kg/day). In the kidneys 
the lesions were characterized by vacuolar degeneration and focal coagulative necrosis of the 
proximal tubules (lowest LOEL: 250 mg/kg/day). The renal lesions were judged to be mild to 
moderate. Chlorobenzene induced moderate to severe lymphoid necrosis of the thymus in male 
and female mice (lowest LOEL being obtained in males: 250 mg/kg/day). However, there was 
no perfect dose-response relationship with regard to this effect of chlorobenzene. Lymphoid 
depletion of the thymus, lymphoid and myeloid depletions of the spleen, and myeloid depletion 
of the bone marrow, all regarded as minimal to moderate, were only seen in animals in the 
highest dose groups. Taken together, the results suggested a NOEL of 125 mg/kg b.wt./day. 
Mice appeared to be more sensitive toward the toxic effects of chlorobenzene, and males were 
somewhat more sensitive than females.
The subchronic toxicity of inhaled chlorobenzene has been evaluated in male rats and rabbits 
(28). The animals were exposed to 0, 75, or 200 ppm (0, 345, or 920 mg/m3) of chlorobenzene 
for 7 hr/day, 5 days/week, for up to 24 weeks. Groups of animals were killed after 5, 11, and 
24 weeks and examined for hematology, clinical chemistry, and gross and histopathological 
changes. Chlorobenzene-related toxicity in the male rats included decreased food utilization, 
increased liver weights, lowered ASAT activity at all survival times, increased number of 
blood platelets after 11 weeks of exposure and microcytic anemia. Histopathological changes 
observed were occasional focal lesions in the adrenal cortex, tubular lesions in the kidneys, 
and congestion in both liver and kidneys. Reported toxic effects in the rabbits included 
increased lung weights and, after 11 weeks of exposure, decreased ASAT activity. The results 
were presented in a short meeting abstract that did not include any information on, for example, 
strains, number of animals, or nonobserved effect levels.
The subchronic toxicity of chlorobenzene has also been investigated in dogs, exposed either 
orally or by inhalation. The only published information from these studies available for 
evaluation, is a condensed meeting abstract by Knapp et al. (53) briefly reporting the results 
from the oral studies where chlorobenzene was administered via gelatine capsules. One of the 
subchronic toxicity studies on dogs, performed by Hazleton Laboratories, USA, for Monsanto 
Company, USA [project numbers 241-105, 1967 and 790015/DMEH ML-79-025, 1980], 
have been cited, and/or, evaluated by others (6, 25, 32). According to the U.S. EPA (32), the 
toxicity of chlorobenzene has also been tested in a 90-day inhalation study of male and female 
beagle dogs by Industrial Bio-Test Inc. (IBT), for the Monsanto Company [BLT-project no. 
76-166, 1979; unpublished].
In the IBT-study, groups of beagle dogs (four males and four females in each group) were 
exposed to 0, 0.75, 1.5, or 2 mg/1 air (0, 750, 1,500 or 2,000 mg/m3) of chlorobenzene vapors,
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6 hr/day, 5 days/week for 90 days. Some of the animals in the two highest dose groups (HD: 
5/8; MD: 2/8) became moribund and were sacrificed after approximately 30 days. According 
to the secondary source of information (32), the exposure to chlorobenzene resulted in lowered 
body weight gain (HD dogs), lower leukocyte counts and elevated levels of alkaline phos­
phatase, ALAT and ASAT (HD dogs), lower absolute liver weights (HD females), lower 
absolute heart weights (MD males only) and increased absolute pancreas weights (MD and 
HD  females). Histopathological changes included vacuolization of hepatocytes (HD animals), 
aplastic bone marrow (HD dogs), cytoplasmatic vacuolization of the epithelium of the 
collecting tubules in the kidneys (one male and three males in HD) and bilateral atrophy of 
the seminiferous epithelium of the testes (two males in HD). The results of the IBT-study, as 
reported in the secondary source of information (32), should be interpreted with some 
cautiousness. It is not known if this particular IBT-study has been validated. Consequently, it 
is not known if the study should be judged invalid, pending, supplemental, or valid.
In the inhalation study from Hazleton, six adolescent dogs per sex and group (strain not given), 
were exposed to various levels of chlorobenzene vapors, 6 hr/day, 5 days/week, for 6 months. 
The target levels of chlorobenzene were 0, 0.78, 1.57, or 2.08 mg/1 air (0, 780, 1,570, or 
2,080 mg/m3). Significant changes included decreased absolute adrenal weights in the male 
dogs of the two highest dose groups, increased relative liver weights in the female dogs of the 
two highest dose groups, a dose-related increased incidence of emesis in both males and 
females, and an increased frequency of abnormal stools in treated females. The N O A E L  was 
determined to be 780 mg/m3 (6, 32).
In one of the oral subchronic toxicity studies, male and female beagle dogs were given 
chlorobenzene by capsule at doses of 0, 27.25, 54.5, or 272.5 mg/kg b.wt./day, 5 days/week, 
for 13 weeks (93 days). Four of eight dogs in the highest dose group died within 3 weeks. At 
this dose level, chlorobenzene was found to produce a significant reduction of blood sugar, 
an increase in immature leukocytes, elevated serum ALAT and alkaline phosphatase levels 
and, in some dogs, increases in total bilirubin and total cholesterol (25, 32, 53). In the 
condensed meeting abstract it was stated that there were no consistent signs of chlorobenzene- 
induced toxicity at the intermediate and low dose levels (53), but according to the unpublished 
report, cited by, for example, the U.S. EPA (6, 32), chlorobenzene-related hepatotoxicity was 
observed also among the animals in the intermediate dose-group. Among the dogs in the 
highest dose group, histopathological changes were also observed in the kidneys, gastrointes­
tinal mucosa, and hematopoietic tissues (53). The NOEL in dogs given chlorobenzene orally 
via capsulae appeared to be 27.25 mg/kg b.wt./day.
According to the brief information given in the meeting abstract (53), groups of rats were also 
given chlorobenzene in the diet for 93 to 99 consecutive days (0, 12.5, 50, or 250 mg/kg 
b.wt./day). Reported effects of chlorobenzene were retarded growth (males in the highest dose 
group) and increased liver and kidney weights (“some rats at the high and intermediate levels”), 
resulting in a NOEL of 12.5 mg/kg b.wt./day.
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5.4 Chronic Toxicity
Animals: Apart from a cancer study, carried out as a part of the National Toxicology Program, 
where chlorobenzene was given orally to F344/N rats and B6C3F1 mice, 5 days/week for 
103 weeks (51,68), there were no other chronic toxicity studies available forevaluation. Since 
the NTP study, as other regular cancer bioassays, was concentrated on histopathological data 
and consequently devoid of clinical chemistry, hematological investigation, and urinalysis, 
etc., the study has been evaluated under the heading “Carcinogenicity” on page 48. However, 
it may be useful to note that the administration of up to 120 mg/kg b.wt./day (rats and female 
mice) or 60 mg/kg/day (male mice) of chlorobenzene for 2 years, failed to induce the type of 
toxic responses (e.g., damage to the liver, kidney, and hematopoietic system) that was observed 
in the previously cited subchronic toxicity study in rats and mice (51).
Humans: Human data on the chronic toxicity of chlorobenzene are limited. Other reviews of 
chlorobenzene-associated toxicity (25, 32) mention a paper by Rozenbaum et al. from 1947 
[published in Gig Sanit 12 (1947) 21-24; in Russian], reporting the results of an examination 
of 52 people occupationally exposed to chlorobenzene. Twenty-eight individuals in the study 
had been working for 1 to 2 years in a factory where chlorobenzene vapor was claimed to be 
the only work-related chemical exposure. Many of these individuals were reported to suffer 
from headache, dizziness, somnolence, and dyspeptic disorders.
There is also another Russian paper, by Lychagin et al. from 1976 [published in Gig Tr Prof 
Zabol 11 (1976) 24-26; in Russian], reporting a higher incidence of women with im­
munological shifts, disturbed phagocytic activity of the leukocytes, reduced absorption 
capacity of the neutrophils, dermal infections, occupational dermatitis, and chronic effects to 
respiratory organs in a glass insulating enameling department. Study design, number of 
workers and controls involved, exposure levels, duration of exposure, etc., were not given in 
the short citation (91), but the exposure situation appeared to have been complex, also 
involving exposure to, for example, acrolein, acetone, and glass fiber dust.
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6 ORGAN EFFECTS
6.1 Skin, Eyes, and Other Mucous Membranes
Available information on the acute effects of chlorobenzene in humans (see above) shows that 
chlorobenzene vapors are irritating to the eyes and mucous membranes of the upper respiratory 
tract.
Unpublished experimental data from the German manufacturer Bayer A G  (Suberg 1983a, 
1983b), cited in the German B U A  report (19), showed that chlorobenzene is moderately 
irritating to the skin. The same unpublished studies from Bayer A G  also showed that 
chlorobenzene is a moderate irritant to the eyes (19). No detailed information was given in the 
short citation of these studies, but both the dermal irritancy/corrosivity study, and the eye 
irritation test were performed on rabbits according to the OECD guidelines for testing of 
chemicals (19).
6.2 Respiratory System
Results obtained in some of the general toxicity tests show that chlorobenzene may be toxic 
to the lung. Necrotic lesions in the bronchial epithelium of the lungs are one of the chloroben- 
zene-induced histopathological changes that have been observed in acute toxicity tests after 
administration of large doses. A subchronic toxicity study of inhaled chlorobenzene in rabbits 
(28) showed increased lung weights after up to 24 weeks of exposure to 75 or 200 ppm 
chlorobenzene.
Apart from the fact that inhalation of chlorobenzene vapors is irritating to the membranes of 
the upper respiratory tract, no other human data have been found with regard to the chloro- 
benzene-induced adverse effects on the lungs.
The lungs are evidently not the major targets for the chlorobenzene-induced toxicity. The 
reported effects from animal experiments were observed only at relatively high exposure 
concentrations of the compound.
6.3 Liver
Animals: As discussed above in the section “General Toxicity,” the liver is one of the main 
targets for chlorobenzene-induced toxicity. Studies on experimental animals have shown that 
chlorobenzene produces various types of deleterious effects on the liver, both morphological 
and functional. Typical consequences of chlorobenzene exposure are increased liver weights, 
increased activities of serum liver enzymes, porphyria, and hepatocellular necrosis. This has,
for example, been observed in male and female rats after both acute and repeated oral 
administration and inhalation (22,46,51,53,67,68), in male and female mice after acute and 
repeated oral exposure (51,53), in dogs given the compound orally or by inhalation for several 
weeks (6, 25, 32, 53) and in pregnant rabbits after inhalation of chlorobenzene vapor during 
the period of gestation (48).
A carcinogenicity study on Fischer 344/N rats (51,68) showed that there was a slight increase 
in the frequencies of male rats with neoplastic nodules of the liver after two years of oral 
exposure to 120 mg chlorobenzene/kg b.wt./day. No such changes were observed in male rats 
receiving a lower dose, female rats, or in male and female B6C3F1 mice (see p. 48).
In a study of chlorobenzene-induced hepatotoxicity, male Sprague-Dawley rats were injected 
for three consecutive days with physiological saline or phenobarbital before they were given 
an i.p. injection with various doses of chlorobenzene diluted in sesame oil (17). The animals 
were killed 24 hr after the injection with chlorobenzene. The livers were removed and 
examined histopathologically. The pathological changes of the hepatocytes in the centrilobular 
region in the non-induced rats given 0.04 ml chlorobenzene varied from glycogen loss to 
minimal necrosis. However, the centrilobular necrosis in the phenobarbital-pretreated rats 
given the same amount of chlorobenzene was found to be extensive or massive.
In another single-dose experiment on male Sprague-Dawley rats (22), the relative liver weights 
were found to be increased about 1.5 times those of the controls 24 hr after an i.p. injection of
9.8 mmol/kg b.wt. At this time a mild but progressive development of a hepatic lesion was 
observed around the central veins. The damage was manifested as a cloudy swelling and 
hydropic changes of the centrilobular hepatocytes. Forty-eight hr after the injection, the signs 
of necrosis had become even more pronounced. Rats given 9.8 or 14.7 mmol/kg (1,100 or 
1,655 mg/kg), showed extensive hydropic changes throughout the liver and clear evidence of 
necrosis. However, signs of mild morphological alterations (cloudy swelling and hydropic 
changes in centrilobular regions) were also present at the lowest dose level tested 
(2.0 mmol/kg; 225 mg/kg). No evidence of fatty changes was observed at any dose level or 
survival time.
In a study on the relationship between the chemical structure of chlorinated benzenes and their 
effects on hepatic and serum lipid components, chlorobenzene was given to male Sprague- 
Dawley rats in the diet at a concentration of 500 ppm for two weeks (46). Whereas the body 
weight gain and kidney and spleen weights were unaffected, the liver weights were slightly 
increased. The level of lipid peroxide was reported to be increased in the livers of the 
chlorobenzene-exposed rats and this increase was accompanied by an elevated level of 
triglycerides and lowered levels of vitamin E and glutathione peroxidase.
In order to explore the relationship between chemical structure and liver toxicity, Ariyoshi et 
al. (9) gave various chlorinated benzenes suspended in 2% tragacanth gum solution orally to 
female Wistar rats for three consecutive days. Chlorobenzene was also given as a single oral 
dose of 125, 250, 500, and 1,000 mg/kg b.wt. Among the various parameters investigated in 
controls and exposed rats (six animals/group) were the contents of microsomal proteins,
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including cytochrome P450, and phospholipids, the activities of the drug-metabolizing en­
zymes aminopyrine methylase and aniline hydroxylase, and the activity of a-aminolevulinic 
acid synthetase. Oral doses of 125-1,000 mg/kg b.wt./day for three days were found to increase 
the hepatic heme synthesis but to decrease the microsomal cytochrome P450 content as well 
as the activity of aminopyrine demethylase. The activity of a-aminolevulinic acid synthetase 
was markedly increased at all dose levels employed. Liver weights and the contents of fatty 
acids of phospholipids were increased in the chlorobenzene-exposed animals, but there were 
no compound-related effects on the contents of glycogen, triglycerides, or the total amount of 
microsomal proteins.
Obviously, chlorobenzene differs from many polychlorinated aromatic hydrocarbons, in not 
being a general inducer of the microsomal metabolism (i.e., the compound does not stimulate 
the activity of the cytochrome P450/P448 enzyme system). This conclusion has subsequently 
been confirmed in experiments performed on male Sprague-Dawley rats given a single i.p. 
injection of chlorobenzene (22).
One way of studying liver toxicity is to monitor the serum alanine aminotransferase (ALAT) 
activity. This enzyme is regarded highly specific to the liver, and its concentration in the blood 
is regarded directly proportional to liver damage. Several investigations have shown that 
chlorobenzene exposure is associated with increased serum ALAT activity. In one of these 
experiments (22), already mentioned above, chlorobenzene was given diluted in com oil as a 
single i.p. injection of 2, 4.9, 9.8, or 14.7 mmol/kg b.wt. (225, 550, 1,100 or 1,655 mg/kg) to 
male Sprague-Dawley rats. Controls received vehicle only. The effects of chlorobenzene were 
also investigated after various intervals (3 to 72 hr) following a dose corresponding to the 
estimated LDio dose (1,100 mg/kg b.wt.). Each group of chlorobenzene-treated rats consisted 
of two to six animals. The ALAT activity was found to be significantly elevated at all intervals 
studied, the maximum increase being observed after 48 hr. The dose-response experiment 
showed elevated ALAT activities at all doses tested, but the authors considered 1,100 mg/kg 
b.wt. to be the LOEL with regard to this specific experimental parameter. Chlorobenzene was 
also found to elevate the sulphobromophtalein (BSP) retention significantly at all intervals 
studied. The maximum effect was already obtained 3 hr after the injection. Consequently, 
functional evidence of hepatotoxicity can be detected early in the time course of events induced 
by chlorobenzene.
In another study (83) employing male B6C3F1 mice, chlorobenzene was given as an i.p. 
injection at doses of 0 (com oil) 0.01, 0.1, 0.25, 0.5, or 1 ml/kg b.wt. (higher doses than that 
resulted in 100% lethality within 24 hr after the injection). Each group consisted of at least 
nine animals. As in the above-mentioned study on the male Sprague-Dawley rats, the 
maximum increase of serum ALAT activity was obtained 48 hr after the injection. The LOEL 
with regard to increased serum ALAT activity in the male mice was established at 0.5 ml/kg 
b.wt.
Another typical effect of chlorobenzene on the liver, is its influence on the glutathione levels. 
Glutathione is a tripeptide that is involved in the detoxification of electrophilic substances. 
The reaction between the nucleophilic groups in glutathione and electrophilic sites in reactive
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molecules often leads to the formation of mercapturic acids that are excreted in the bile or, as 
in the case of chlorobenzene, in the urine.
In one of the studies investigating the effect of chlorobenzene on the GSH levels in the liver 
(95), male Wistar rats were given an i.p. injection of chlorobenzene diluted in olive oil. The 
compound was given either as a single dose of 2 mmol/kg b.wt. (225 mg/kg), or repeatedly 
four times during a 48-hr period (4x2 mmol/kg b.wt.). In the single-dose experiment, the rats 
were sacrificed after 3,6,24, and 30 hr, and in the repeat dose experiment, they were sacrificed 
either 48 hr after the first injection or 48 hr after the last injection. Each group consisted of 
four to five animals. Controls received olive oil only. In the single-dose experiment, chloroben­
zene was found to induce a significant, but transient, decrease of the hepatic levels of total and 
oxidized glutathione. Six hr after the injection, the total amount of glutathione was only 24% 
of that in the controls. However, 24 hr after the injection, there was already a significant 
increase of both the total and oxidized glutathione (188% and 170% of controls, respectively), 
an effect that was accompanied by an increased glutathione synthesis (193% of controls) and 
an elevated glutathione reductase level (136% of controls). After 48 hr, all these levels were 
still increased, and at this survival time the liver weights, as well as the protein- and 
DNA-contents, were also found to be significantly increased. The repeat dose experiment 
confirmed the chlorobenzene-induced liver enlargement and accumulation of hepatic 
glutathione.
Initial depletion of glutathione levels shortly after an intraperitoneal injection of chlorobenzene 
to male Sprague-Dawley rats was also observed in the previously mentioned study by Dalich 
and Larson (22). Four hr after the injection, there was a significant depletion of GSH levels at 
all doses investigated (from 2.0 to 14.7 mmol/kg b.wt.). Apart from the lowest dose group, 
the GSH levels remained low 8 hr after the injection, the longest survival time employed for 
this study parameter. The experiments also included measurements on the potential effects of 
chlorobenzene on the microsomal cytochrome P450 levels in the liver. Four hr after the 
administration, these were found to be depressed between 30-50% at all dose levels tested. 
After 24 hr, the cytochrome P450 content was lowered to 50-80% of the control level. 
However, there was no obvious relationship between the dose and the observed effect on the 
cytochrome P450 content. With regard to the time course of the covalent binding of 
[14C]chlorobenzene-associated radioactivity to liver proteins, measurable amounts were al­
ready present 2 hr after the injection. The amount of binding increased steadily during the first 
24 hr. Again there was a poor correlation between the dose and the magnitude of the covalent 
binding to the liver proteins, the maximum covalent binding being obtained at 4.9 mmol/kg 
(550 mg/kg).
Experiments on male B6C3F1 mice showed temporal changes in hepatic glutathione con­
centrations following an i.p. injection of chlorobenzene (83). When groups of animals (at least 
8 animals/group) were killed after 2, 4, 8, or 24 hr after an i.p. injection of either com oil 
(controls) or 0.48 ml chlorobenzene/kg b.wt., the hepatic glutathione concentrations were 
found to be depleted maximally 4 hr after the injection of chlorobenzene (90% reduction). 
After 24 hr, the glutathione levels recovered back to normal. In a dose-response experiment, 
groups of mice (at least eight animals in each group) were given 0, 0.01, 0.1, 0.25, or 1 ml
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chlorobenzene/kg b.wt. i.p. and sacrificed 3 hr later. It was reported that 0.1 ml/kg was the 
lowest effective dose that significantly exhausted the liver GSH. However, there was no perfect 
dose-response relationship for this effect (0.1 ml/kg: 23% reduction; 0.25 ml/kg: 78% 
reduction; 0.1 ml/kg: 76% reduction and 1.0 ml/kg: 71% reduction).
Humans: A  recently published case report from France (13) described quite severe effects on 
the liver by chlorobenzene. Exposure occurred in a suicide attempt in which a 40-year-old 
man ingested approximately 140 ml of a 90% chlorobenzene solution. After two hr, the patient 
became drowsy. At that time the serum activities of ASAT and ALAT were increased 
approximately three times. Three days after the ingestion of chlorobenzene, the serum ASAT 
and ALAT activities were 345 and 201 times the upper limits of normal, respectively. The 
liver was not enlarged, but the patient had a diffuse erythema covering the face. A  liver 
specimen was taken by transjungular biopsy. The histopathological examination showed 
centrilobular and mediolobular necrosis, but no evidence of inflammatory infiltration, 
hepatocyte ballooning or fibrosis. Immunoglobulin M  antibodies to hepatitis A  virus and to 
hepatitis B core antigen, as well as hepatitis B surface antigen, were absent, and the serological 
test results for recent infection with herpes simplex viruses were negative. The serum level of 
chlorobenzene was determined to be 500 jig/13 days after the suicide attempt, and 2 jag/1 after 
15 days. Although the man was described as an alcoholic (the consumption of alcohol was 
estimated to 200 g per day), the authors concluded that the observed liver cell necrosis was 
directly linked to the acute intake of chlorobenzene (there was, for example, no history of 
chronic liver disease, which was also confirmed by the liver biopsy). However, it cannot be 
ruled out that the chronic ethanol consumption might have played a role in the severity of the 
observed lesions. After being treated with prostaglandin Ei for several days, the patient 
recovered.
Apart from the above-mentioned case report, no other data was found concerning hepatotoxic 
effects of chlorobenzene in humans. However, it may be worth noting that results obtained in 
vitro (50) suggest that humans may be more susceptible to the hepatotoxic effects of 
chlorobenzene than rodents. Liver microsomes taken from humans were reported to be more 
efficient in producing p-chlorophenol than mouse liver microsomes, showing that the main 
metabolic pathway of chlorobenzene in human livers is through the hepatotoxic 3,4-epoxide 
pathway (see p. 12).
6.4 Kidneys
Animals: As shown in the previously discussed general toxicity studies, but also in other 
toxicity tests (see p. 53), the kidney is another target for chlorobenzene-induced toxicity. This 
has also been shown in experiments designed to investigate the mechanisms behind the 
nephrotoxic action of chlorobenzene (75). Male Sprague-Dawley rats and male C57BL/6J 
mice given a single i.p. injection of unlabelled and/or 14C-labelled chlorobenzene, 
developed a renal tubular lesion within 48 hr. Extensive necrosis of the proximal convoluted renal 
tubules was, for example, observed among 80% of the mice given 6.75 mmoles/kg b.wt. 
(760 mg/kg). The rats were not as sensitive as the mice to the nephrotoxic action of chlorobenzene.
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The development of renal necrosis was associated with covalent binding of chlorobenzene- 
associated radioactivity to kidney proteins. After administration of 14C-chlorobenzene 
(1 mmol/kg b.wt.; 10-30 jiCi/animal), a considerable amount of chlorobenzene-associated 
radioactivity became covalently bound in the region with the necrotic lesions, i.e., in the 
proximal convoluted tubule cells. The nephrotoxic action of chlorobenzene could be reduced 
if the animals were pretreated with piperonyl butoxide, an inhibitor of microsomal enzymes. 
The pretreatment did not only block the renal toxicity, it also markedly reduced the binding 
of chlorobenzene-associated radioactivity to the kidney proteins. However, in contrast to the 
situation in the liver (see above), pretreatment with phenobarbital, an inducer of microsomal 
enzymes, did not significantly enhance the nephrotoxicity of chlorobenzene in the rats and 
mice.
Humans: No data was found concerning nephrotoxic effects of chlorobenzene in humans.
6.5 Pancreas
In a study on the effects on the pancreas of benzene and various halogenated analogues, 
including chlorobenzene, male Holzman rats were given an i.p. injection of 5 mmol/kg b.wt. 
(562.5 mg/kg) of chlorobenzene (94). Controls received an i.p. injection of the vehicle, sesame 
oil. Each group of animals consisted of at least 4 animals. Twenty-four hr after the 
injection, surgery was performed on phenobarbital anesthetized animals, cannulating the 
femoral vein and the common bile duct. Bile duct pancreatic fluid (BDPF) and bile were 
collected separately. Chlorobenzene as well as most of the other compounds investigated 
(e.g., bromobenzene and benzene) altered the pancreatic excretory function. In the case of 
chlorobenzene, this was manifested as a 10-fold increase in BDPF flow, a significant decrease 
in protein concentration of BDPF (70% reduction), and an increased bile flow. The 
mechanism(s) behind the observed effects remains unknown. Apparently these were not 
induced by secretin or cholinergic stimulation or secondary to liver damage.
The significance of the reported effects of chlorobenzene on the pancreatic excretory function 
is not known. None of the other identified studies on the toxicity of chlorobenzene in 
experimental animals (with the possible exception of the 90-day inhalation study on dogs from 
IBT, see p. 25) reported any compound-related effects in the pancreas.
There is no human data available on chlorobenzene-induced effects in the pancreas.
6.6 Gastrointestinal Tract
Acute toxicity studies on experimental animals have shown that exposures to high doses of 
chlorobenzene are associated with necrosis in the stomach as well as submucosal hemorrhages. 
In an oral subchronic toxicity study in dogs (53), it was noted that the animals given the highest 
dose of chlorobenzene (272.5 mg/kg b.wt., 5 days/week for 13 weeks) developed his- 
topathological changes in the gastrointestinal mucosa.
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No data was found concerning chlorobenzene-induced effects in the gastrointestinal tract of 
humans.
6.7 Circulatory System
Apart from an isolated case of intoxication where a 2-year-old boy was reported to suffer from 
vascular paralysis (an effect that could be due to CNS-depression) after having swallowed 
chlorobenzene (see p. 23), no other data were available on chlorobenzene-induced effects on 
the circulatory system.
6.8 Hematological System
Animals: It has been reported from various experiments in animals that exposure to chloroben­
zene is associated with some hematopoietic toxicity. Male and female Swiss mice were 
exposed to chlorobenzene vapor, either to 100 mg/m3 (22 ppm), 7 hr/day for three months or 
to 2,500 mg/m3 (544 ppm), 7 hr/day for 3 weeks (97). The number of animals in each group 
was ten (5 males and 5 females). During the experiment, and after its termination, blood was 
drawn from the tail vein and examined for the leukocyte counts and blood picture. Com­
parisons were made with controls and mice receiving either benzene or trichlorobenzene. 
Chlorobenzene-induced leukopenia (characterized by neutropenia, destruction of lym­
phocytes and lymphocytosis) and a general bone marrow depression. Similar effects were 
observed in the benzene-exposed mice. However, in comparison to the latter compound, 
chlorobenzene was found not equally potent in inducing hematopoietic toxicity.
According to secondary sources of information (32, 92), Varhavskaya reported pathologic 
changes (inhibition of erythropoiesis, thrombocytosis and mitotic activity) in the bone marrow 
of male rats given oral doses of 0.01 or 0.1 mg chlorobenzene/day for 9 months. The results, 
which were presented in a paper originally published in Russian [Gig Sanit 33 (1968) 17-23], 
were not available for a critical examination. However, the results appear unrealistic, at least 
if the indicated dosages are correct. There is no evidence from any of the other available toxicity 
studies on rats (or other species) that chlorobenzene would be such a potent toxin to the bone 
marrow.
In a previously mentioned inhalation study on male rats and rabbits exposed to 75 or 250 ppm 
(345 or 1,150 mg/m3) chlorobenzene vapors for 11 weeks (28), both species showed un­
specified pathological changes in various red cell parameters.
A  dose-related increase of the number of micronucleated polychromatic erythrocytes was 
observed in the bone marrow of male NMRI mice given i.p. injections of 225-900 mg 
chlorobenzene/kg b.wt. (65, 66). No information was given on the potential general bone 
marrow toxicity of the substance (see p. 43).
Minimal to moderate myeloid and/or lymphoid depletions were observed in the spleen and 
thymus in another previously mentioned subchronic toxicity study on rats and mice given 
chlorobenzene by gavage for 13 weeks (51, 68). Effects on the bone marrow were only seen
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in animals given the highest dose of chlorobenzene (750 mg/kg b.wt.). An increased number 
of blood platelets and microcytic anemia were observed in male rats and rabbits exposed to 
up to 200 ppm chlorobenzene vapor (920 mg/m3) for up to 24 weeks (28). Histopathological 
changes in hematopoietic tissues have also been reported in an oral subchronic toxicity study 
in dogs given 272 mg chlorobenzene/kg b.wt., 5 days/week for 13 weeks (53).
Humans: There are no relevant data available in the literature on chlorobenzene-induced 
effects on the hematological system in humans.
6.9 Immunological System
Subchronic toxicity studies in mice and rats showed that repeated exposure to relatively high 
doses of chlorobenzene produced minimal to moderate lymphoid depletion of the thymus, and 
lymphoid or myeloid depletions of the spleen and moderate to severe lymphoid necrosis of 
the mouse thymus (51, 68).
No relevant human data was available on chlorobenzene-induced toxic effects on organs and 
tissues constituting the immunological system.
6.10 Central Nervous System
Most organic solvents are to a greater or lesser extent able to induce CNS-depression when 
given at large doses. The neurotoxic effects of organic solvents may be divided into acute 
effects and chronic effects. Generally it is assumed that whereas the acute effects may be a 
result of the direct action of the solvent on the nerve cell membrane and energy metabolism, 
the chronic effects are caused by the formation of reactive intermediates (80). In the case of 
chlorobenzene, no information was available with regard to possible chronic neurotoxic effects 
of the compound. However, its potential to induce acute neurotoxic effects is well documented.
It is known that even a short duration of exposure to low concentrations of various solvents 
can induce moderate signs of toxicity such as mucous membrane irritation, tearing, nasal 
irritation, headache and nausea. At higher exposure levels, the toxic effects become more 
pronounced and may include overt signs of intoxication, incoordination, exhilaration, sleepi­
ness, stupor, and beginning anesthesia (27). While the former group of symptoms combined 
can be viewed as prenarcotic effects, the latter symptoms are generally regarded as indicators 
of narcosis (27). However, it may be difficult to establish safe exposure limits with regard to 
the solvent-induced CNS effects following from short-term exposure. Many of the mild 
symptoms described above are subjective, tolerance is often developed, the estimated exposure 
levels are often uncertain and the recorded effects are in many cases reversible. It has therefore 
been argued that it would be better to use various forms of neurobehavioural tests that measures 
basic psycho-physiological functions such as alertness, reaction time, memory, and sensory - 
motor performance as indicators of mild CNS-effects, instead of reported signs of mild 
intoxication (27).
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Animals: As previously discussed, acute symptoms of chlorobenzene-induced intoxication in 
various species of experimental animals include CNS effects such as excitation followed by 
drowsiness, adynamia, ataxia, paraparesis, paraplegia, and dyspnea (see p. 21).
A specific study on behavioral changes following short-term inhalation of chlorobenzene was 
performed in male Swiss OF1 mice (24). The animals were exposed for 4 hr to high 
concentrations of chlorobenzene vapor: 650,785, 875, or 1,000 ppm (i.e., 2,990, 3,610,4,025, 
or 4,600 mg/m3), respectively. Controls were exposed to clean filtered air only. The number 
of animals in each group was ten. Measurements were made to see whether the acute exposure 
affected the immobility developed in a so-called “behavioral despair” swimming test. The test 
is based on the fact that rodents that are forced to swim in a limited space, after a while develop 
a characteristic immobile posture that can be timed. Chlorobenzene, as well as other solvents 
included in the study, was found to reduce the total duration of immobility over a 3-min period 
in a dose-related manner. The exposure that would give a 50% decrease in immobility was 
estimated to be 804 ppm (i.e., 3,700 mg/m3) for chlorobenzene. This level was considerably 
higher than, for example, that calculated for benzyl chloride (15 ppm) and styrene (549 ppm), 
but notably lower than that calculated for other solvents such as 1,2-dichloroethylene 
(1,983 ppm), methyl ethyl ketone (2,056 ppm) and 1,1,1-trichloroethane (2,729 ppm).
Humans: As previously discussed, isolated case reports of acute poisonings have shown that 
inhalation or ingestion of high doses of chlorobenzene is associated with CNS-effects such as 
drowsiness, incoordination, and unconsciousness (see p. 23). In the previously mentioned 
controlled exposure chamber study (71) where five male volunteers were exposed to 
chlorobenzene vapors for up to 7 hr, a significant decrease in flicker-fusion values, indicating 
a lowered perception, was observed after 3 hr of exposure to 60 ppm (275 mg/m3). Subjective 
symptoms reported after 7 hr of exposure were drowsiness, headache, irritation of the eyes, 
and sore throat.
6.11 Reproductive Organs
A two-generation reproductive toxicity study on rats (67) showed that chlorobenzene induced 
dose-related changes in the testes. These were manifested as an increased incidence of males 
with a degeneration of the testicular germinal epithelium in the highest dose group (450 ppm 
in the diet). Despite these lesions, there were no adverse effects on the reproductive perfor­
mance or fertility. The results of the reproductive toxicity study are described in more detail 
starting on p. 51.
Bilateral atrophy of seminiferous epithelium of the testes was also noted among some of the 
male beagle dogs that were exposed to 273 ppm chlorobenzene vapor for 90 days in the 
previously discussed IBT-study (see pp. 25-26).
6.12 Other Organs
Apart from the organs mentioned above, chlorobenzene has also been found to affect the 
adrenals of male dogs and rats in subchronic inhalation toxicity tests (28, 53). In the dogs, the
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effect on the adrenals was manifested as decreased absolute adrenal weights in animals 
exposed to 1,570 or 2,080 mg/m3 chlorobenzene vapor, 6 hr/day, 5 days/week for 6 months. 
In the rats, the toxicity was manifested as occasional focal lesions in the adrenal cortex (the 
inhalation concentrations of chlorobenzene in the latter study were 345 or 920 mg/m3,7 hr/day, 
5 days/week up to 24 weeks).
The significance of these findings is not known, and there are no other reports on 
chlorobenzene-induced adrenal toxicity in any of the other identified toxicity studies.
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7  IM M U N O T O X IC IT Y  A N D  A L L E R G Y
Animals: Aranyi et al. (8) investigated the effects of single and multiple 3-hr exposures to 
TLV-concentrations of various industrial compounds (75 ppm for chlorobenzene) in female 
CD 1 mice by monitoring their susceptibility to experimentally induced streptococcus aerosol 
infection and pulmonary bacterial activity to inhaled Klebsiella pneumoniae. The results of 
the study have also been presented in a short notice (5). Whereas, for example, methylene 
chloride, ethylene chloride and toluene affected both investigated experimental parameters, 
chlorobenzene apparently lacked significant effects on the murine lung host defenses.
The German B U A  report on chlorobenzene (19) cited an unpublished study from Bayer A G  
(Mihail 1984) reporting that chlorobenzene did not induce skin sensitization (i.e., did not 
induce allergic contact dermatitis) in the so-called maximization test using male guinea pigs. 
No further information was given in the short citation.
Humans: No relevant reports were available with regard to immunotoxic or allergic effects 
of chlorobenzene in exposed humans.
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8  G E N O T O X IC IT Y
The results from the testing of the genotoxicity of chlorobenzene in various test systems are 
not consistent. The overall data seem to show “limited evidence of genotoxicity” since 
chlorobenzene was reported “positive” in at least three different test systems measuring 
mutagenicity, chromosomal anomalies and D N A  damage/DNA-binding (most of the other test 
results were reported as “negative”).
Most of the published data on the potential genotoxicity of chlorobenzene are summarized in 
Table 2. However, as indicated below, there are also some additional tests on the genotoxicity 
of chlorobenzene. Although cited, these are in general either unpublished studies performed 
by, or on behalf of, various chemical manufacturers, or reports written in a language not 
familiar to the evaluator. Consequently, it has not always been possible to judge the validity 
or significance of each individual result, as reported by others.
No human data are available on possible genotoxic effects following from accidental, 
occupational or environmental exposure to chlorobenzene.
8.1 Gene Mutations
The ability of chlorobenzene to induce gene mutations (point mutations) has been investigated 
in various strains of Salmonella typhimurium (43, 82), in one strain of Aspergillus nidulans 
(74), and in one mammalian cell system, the L5178Y mouse cell lymphoma assay (62). 
Chlorobenzene was found mutagenic in the mammalian test system, but without effects in the 
two reverse mutation test systems based on nonmammalian cells. The absence of a mutagenic 
effect in the various strains of S. typhimurium, and the presence of a mutagenic effect in the 
L5178Y cells, was not affected when a metabolic activation system was added to the test 
systems.
Reverse mutations in bacteria: One of the two recognized and published reverse mutation 
assays in Salmonella (82) was performed as a standard plate incorporation assay. The 
mutagenicity was tested both in the absence and presence of a liver microsomal fraction (the
S9-fraction was prepared from livers from male Sprague-Dawley rats pretreated with a 
polychlorinated biphenyl). Five different strains of S. typhimurium were used: TA1537, 
TA1538, TA98 (for the detection of frameshift mutations), TA1535 and TA100 (for the 
detection of base pair substitutions). Chlorobenzene was diluted in D M S O  and tested in a 
series of concentrations from 0.02 jal to 1.28 jal per plate (the highest concentration was clearly 
toxic in all strains), without being mutagenic.
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In the other Salmonella/mammalian microsome assay (43,68), a preincubation procedure was 
used instead of the standard plate protocol when testing the potential mutagenicity of 
chlorobenzene (and 349 other coded chemicals). Four different strains of S. typhimurium 
were used: TA1535; TA1537; TA98 and TA100. The potential mutagenicity was tested both 
with and without an exogenous metabolic activation system (liver S9-fractions from male 
Sprague-Dawley rats and Syrian hamsters induced with Aroclor 1254). Chlorobenzene was 
dissolved in D M S O  and tested in concentrations ranging from 33.3 to 3,333.3 pg/plate. In 
contrast to a positive control, chlorobenzene did not increase the number of revertants in any 
of the strains tested.
The final draft of the health effect criteria document from EPA (32), and the B U A  report (19), 
referred to other Salmonella!microsomal assays than those mentioned above. Since none of 
these appear to have been published [one study from Monsanto 1976 performed at Litton 
Bionetics; one from Dupont 1977 performed at Haskell Laboratory; one from Merck 1978 and 
one performed by Simmon, Riccio, and Peirce 1979], it has not been possible to evaluate them 
in the present document. All were reported negative, including an investigation on E. coli 
WP2. In the EPA document (32), it was noted that the statistical analysis of the data in these 
studies did not include information on the number of revertants per unit of survivors.
The ability of chlorobenzene to induce point mutations has apparently also been tested by 
Koshinova in an assay based on Actinomyces antibioticus 400. According to the brief details 
given in secondary sources of information (6, 92), chlorobenzene was reported to induce 
reverse mutations in the presence of an exogenous metabolic system. The original study (the 
information on where this article was published varies, but it appears to have been in Genetica 
4 (1968) 121-125; presumably in Russian) was not available for evaluation and it has 
consequently not been possible to evaluate the significance of the reported “positive” effect 
in the indicated test system (not one of the most established short-term tests for genotoxicity).
Reverse mutations in moulds: An auxotroph strain of Aspergillus nidulans requiring 
methionine and pyridoxine was used when testing for the ability of chlorobenzene to induce 
reverse mutations (72). A  suspension of freshly prepared spores was added to a 6% diethyl 
ether solution of chlorobenzene. After 1 hr of exposure, the mixture of compound, vehicle and 
spores was diluted and a fraction was spread over pyridoxine and methionine-supplemented 
minimal medium plates. The number of conidia (revertants) was estimated using a 
hematocytometer after 5 days of incubation at a temperature of 28°C. Chlorobenzene was 
tested at one concentration only (200 fig/ml). At this concentration there were no significant 
differences in survival or number of revertants between the controls and treated. It may be 
worthwhile to note that this particular test system has not been evaluated and validated to the 
same extent as, for example, the Salmonella/mammalian microsome assay, the L5178Y mouse 
lymphoma assay, or the micronucleus test, and it is not clear whether the testing conditions 
were optimal with regard to, for example, temperature or pH (known to be of importance at 
least in other types of tests involving fungi).
Sex-linked recessive lethal mutations in Drosophila melanogaster: Apparently there is at 
least one unpublished report (90) on the effects of chlorobenzene in the so-called Drosophila
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sex-linked recessive lethal test (the SLRL test). The ability of chlorobenzene to induce 
sex-linked recessive lethal mutations in postmeiotic germ cells was evaluated in males 
(wild-type stock, Canton-S) that had been exposed to at least 9,000 ppm chlorobenzene for 
4 hr (36,000 ppm-hr) or 10,700 ppm for 3 x 4 hr (128,400 ppm-hr) before the surviving flies 
were mated with three sets of virgin “Base” females for 72 hr each. There was no indication 
of any mutagenic effect in any germ cell stage. The original report was not available at the 
time of the present evaluation and it has consequently not been possible to evaluate the 
experimental conditions, etc., in great detail.
Forward mutations in mammalian cells in vitro: The L5178Y mouse cell lymphoma assay 
is a well-established test system when screening for gene mutations in vitro. The test system 
identifies agents that can induce forward mutations in the thymidine kinase locus (TK-locus). 
Cultures of L5178Y, clone 3.7.2C, were exposed to chlorobenzene for 4 hr and then cultured 
for 2 days, before plating in soft agar with or without trifluorothymidine (62). Four experiments 
were performed without S9 (postmitochondrial supernatant fractions of liver homogenate from 
male Fischer 344 rats pretreated with Aroclor 1254), and two experiments in the presence of 
the metabolic activation system. Well established mutagens were included in the test as 
positive controls, and the solvent (DMSO) as a negative control. The dose range varied from 
6.25 to 195 fig/ml (without S9) and from 70 to 190 (with S9). The highest concentrations were 
toxic to the cells. Without S9, two of the four tests yielded inconclusive results, the two others 
were positive (lowest effective concentration being 100 pg/ml). The two experiments with S9 
gave significant and consistent positive responses, showing a mutagenic effect of chloroben­
zene.
The final draft of the health effect criteria document from EPA (32) and the German B U A  
report (19), also mentioned the results of an unpublished mouse lymphoma L5178Y cell 
culture assay from Monsanto 1976 (testing being performed by Litton Bionetics). In contrast 
to the study referred to above, chlorobenzene was found to lack mutagenic effects [at 
0.001 |Lil/ml without enzymatic activation, and at 0.001-0.01 fil/ml with activation]. The 
Monsanto study was not available for evaluation and it has consequently not been possible to 
judge the significance of the reported “negative” results.
8.2 Structural Chromosomal Aberrations
Chromosomal aberrations in mammalian cells in vitro: The ability of chlorobenzene to 
induce chromosomal aberrations has been investigated in cultured Chinese hamster ovary 
cells, CHO-cells, with and without the addition of a metabolic activation system (60). The S9 
rat liver microsomal fraction, which was used as metabolic activation system, was prepared 
from Aroclor-1254-induced male Sprague-Dawley rats. D M S O  was used as vehicle and 
cyclophosphamide (with activation) and mitomycin C (without metabolic activation) as 
positive controls. Chlorobenzene was tested at the following concentrations: 0, 30, 100, 300, 
or 500 (without activation), 0, 50, 150, or 510 (experiment one with activation) and 0, 150, 
300, or 500 (experiment two with metabolic activation) pg/ml. Approximately 24 hr 
before the exposure, cultures were initiated at a cell density of 1.75 x 106 cells/flask. In the 
experiment without activation, the cells were incubated with chlorobenzene for 8 hr, before
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they were treated with colchemid for 2-2.5 hr before harvest. In the experiments with 
activation, the cells were incubated with the substance and S9 for 2 hr, then cultivated with 
medium only for another 8 hr. Colchemid was then added 2 hr before cell harvest. One hundred 
cells were scored for each of three concentrations (the highest test concentration containing 
sufficient metaphase cells, and two lower concentrations, covering a 1-log range). An increase 
of chromatid breaks was seen at one intermediate dose (150 fig/ml) in the first of two trials 
with S9. However, this effect was not reproducible in the second experiment. No aberrations 
were induced in the absence of a metabolic system up to a dose of 500 Jig/ml, a concentration 
that was found to be clearly toxic to the cells.
Chromosomal aberrations in mammalian cells in vivo: The clastogenic ability of 
chlorobenzene in vivo was evaluated in a micronucleus test employing 8-week old male 
NMRI-mice (65,66). The compound was given intraperitoneally in four different doses (from 
225 to 900 mg/kg b.wt.); the highest amount corresponding to approximately 70% of the i.p. 
LD50 value. The total amount of substance was divided into two equal doses (i.e., 2x112.5 
to 2 x 450 mg/kg) and given 24 hr apart. Each group consisted of 5 exposed animals. The 
number of com-oil-treated controls was 10. The frequency of micronucleated polychromatic 
erythrocytes (MNPCE) was recorded 30 hr after the first injection. Two smears per femur were 
prepared and coded, and from each bone marrow smear, 1,000 polychromatic erythrocytes 
were analyzed for the presence of chromosomal fragments. There was a statistically significant 
and dose-related increase in the number M N P C E  in the mice given chlorobenzene when 
compared to the vehicle-treated controls. No information was given with regard to the potential 
bone marrow toxicity of the compound (i.e., the ratio between the number of normochromatic 
and polychromatic erythrocytes).
Apart from the two above-mentioned studies, there is also a Russian study available on the 
cytogenetic effects of chlorobenzene in bone marrow cells from mice (35). In contrast to 
benzene, chlorobenzene was reported to be without cytogenetic activity. No effects were seen 
in a micronucleus test, in a test for chromosomal aberrations in cells arrested in metaphase or 
in a dominant-lethal test. In each case the doses varied between 3.2 and 400 mg/kg b.wt. The 
article was written in Russian (apart from a short summary in English without any information 
on the number of animals involved, survival times, etc.) and it has consequently not been 
possible to judge the significance of the reported results.
Chlorobenzene has also been tested and reported negative for induction of chromosomal 
aberrations in CHO-cells in an EPA-sponsored, unpublished study by Loveday (cited in 
reference 60). In the latter study, chlorobenzene was tested at lower concentrations than those 
used in the more recent study presented above.
8.3 Numerical Chromosomal Alterations
As early as 1943, Ostergren and Levan reported that chlorobenzene could induce an abnormal 
mitotic cell-division in a test system based on the onion Allium cepa (98). In a short abstract 
without details on experimental design, etc., it was stated that full c-mitosis disturbances were 
observed at a chlorobenzene concentration of 1 m M  (precipitate in water); partial disturbances
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at 0.3 m M  (clear aqueous solution); and normal mitosis at 0.1 mM. The authors suggested that 
the c-mitotic property of chlorobenzene was due to the physical properties of the compound 
and not to its chemical properties.
With the possible exception of the “positive” finding in Allium cepa (the significance of this 
remains uncertain) no studies were available on the ability of chlorobenzene to induce 
aneuploidy, polyploidy or nondisjunction (i.e., numerical chromosomal aberrations). How­
ever, the reported increase in the incidence of micronuclei in bone marrow cells from 
chlorobenzene-exposed mice (65,66), could apart from being interpreted as showing an ability 
to induce microscopically observable additions, deletions or rearrangement of parts of chromo­
somes, possibly also be interpreted as showing a chlorobenzene-induced aneuploidization 
(gain or loss of one or more intact chromosomes).
8.4 Primary DNA-Damage and Binding to DNA
Chemical damage to D N A  can be studied by a variety of methods. Some techniques are nonspecific, 
others are limited to specific types of injuries. With regard to the DNA-damaging effects of 
chlorobenzene, only one published study was available in the literature (93). In this study it 
was reported that chlorobenzene lacked effect on the unscheduled D N A  synthesis in a rat 
hepatocyte DNA-repair test. The so-called hepatocyte/DNA-repair test is a well-established, 
nonspecific test for D N A  damages. An increased DNA-repair synthesis, measured as an 
increased incorporation of tritiated thymidine in nondividing cells, seems a general response 
to various types of D N A  damages. Another approach that has been used was to measure the 
DNA-binding capacity of chlorobenzene, both in vivo and in vitro (20, 40, 73). Using this 
procedure, chlorobenzene was reported to interact directly with DNA.
Induction of DNA-repair in mammalian cells in vitro: After hepatocytes from adult male 
F344 rats had been isolated, freshly prepared monolayer cultures were simultaneously exposed 
to chlorobenzene and 3H-thymidine (93). The exposure time was not clearly stated, but was 
somewhere in the interval of 5-20 hr. After exposure, the cultures were fixed and the thymidine 
incorporation was measured autoradiographically. The criteria used for positive response were 
the following: at least two concentrations must have yielded net nuclear grain counts sig­
nificantly greater than the concurrently run solvent controls; a positive dose-response relation­
ship up to toxic concentrations and at least one of the increased grain counts must have been 
a positive value. Following these criteria, chlorobenzene did not induce DNA-repair synthesis 
in the primary cultures of rat hepatocytes when given in a concentration up to 9.3 x 10'4 M  
(highest nontoxic concentration tested; the dose interval was not given).
The final draft of the health effect criteria document from EPA (32) also mentioned an unpublished 
in vitro study [by Simmon, Riccio, and Peirce 1979] on the DNA-damaging effects of chloroben­
zene in a prokaryotic test system. Chlorobenzene was reported to lack DNA-damaging effects 
in the so-called pol A-test, since it was equally toxic to repair-proficient and repair-deficient 
strains of E. coli when tested at concentrations of 10 or 20 pl/plate.
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Interaction with D N A  in vivo and in vitro: The binding of chlorobenzene and other halogenated 
hydrocarbons to nucleic acids and proteins was studied in various organs of mice and rats, 
both in vivo and in vitro (20, 40, 73). In the in vivo experiments, [U-14C]chlorobenzene 
(20 mCi/mmol) was given in an amount of 127 pCi/kg b.wt. (corresponding to 8.7 pmol/kg 
b.wt.) to groups of 4 male Wistar rats and 12 adult male BALB/c mice. The animals were 
sacrificed 22 hr after the injection. DNA, RNA, and proteins were isolated from the livers, 
kidneys, and lungs. In the in vitro experiments, microsomal and cytosolic fractions were 
extracted from liver, lungs, and kidneys from male BALB/c mice and male Wistar rats, 
pretreated for 2 days with phenobarbital. 14C-labelled chlorobenzene was incubated with 
necessary co-factors and microsomal proteins + NADPH, or cytosolic proteins + GSH, for
60-120 min at 37°C. Similar experimental designs were employed for the other agents tested 
(e.g., bromobenzene, 1,2-dichlorobenzene and benzene).
Radioactivity from all compounds tested, including chlorobenzene, was found to bind 
covalently to the macromolecules in all organs investigated, both in rats and mice, in vivo as 
well as in vitro. The binding appeared to be mediated by the liver microsomes. Although there 
were no profound differences in DNA-binding capacity of chlorobenzene between the various 
organs in vivo, the highest value was observed in the livers from the exposed rats 
(0.26 pmol/mol DNA-P), giving a covalent binding index of 38. This value has been suggested 
to be typical for agents with a weak oncogenic potency (78). The relative reactivity, expressed 
as covalent binding index to rat liver D N A  in vivo, decreased in the following order: 
1,2-dibromoethane > bromobenzene > 1,2-dichloroethane > chlorobenzene > epichloro- 
hydrine > benzene.
Indirect evidence for the ability of chlorobenzene to interact with D N A  has also been presented 
in a study on the elimination of urinary metabolites in rats given a single i.p. injection of 
500 mg chlorobenzene/kg b.wt. (55). Low levels of a guanine adduct, probably identical with 
N7-phenylguanine, were found in the urine on days 1 and 2 and between days 4 and 6 after 
the injection.
8.5 Other Effects on the Genetic Material
In this report, data on sister chromatid exchanges has been treated separately under the heading 
“Other Effects on the Genetic Material.” Representing rearrangements between chromatides 
within a chromosome (only observable with a special staining technique), SCEs do not 
constitute true mutations. However, there is a general agreement that there is a close correlation 
between an increased incidence of SCEs and various types of genotoxic effects. Consequently, 
sister chromatid exchanges may be looked upon as nonspecific indicators of genotoxicity. As 
shown in Table 2, chlorobenzene was found to induce SCEs in Chinese hamster ovary cells.
The ability of chlorobenzene to induce SCEs was investigated using cultured Chinese hamster 
ovary cells, both with and without the addition of a metabolic activation system (60). The 
activation system used was the S9 rat liver microsomal fraction prepared from Aroclor-1254- 
induced male Sprague-Dawley rats. Chlorobenzene was dissolved in DMSO, which also was 
used as the negative control. Mitomycin C was used as the positive control in the absence of,
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and cyclophosphamide in the presence of, the metabolic activation system. Chlorobenzene 
was tested at the following concentrations: 0, 100, 300, or 999 (experiment one without 
activation); 0, 100, 300,500, or 1,000 (experiment two without activation) and 0, 30, 100, and 
300 (with metabolic activation) |ig/ml. Approximately 24 hr after the cultures had been 
initiated (1.25 x 106 cells/flask), the medium was replaced and the cells were exposed to 
chlorobenzene or the control substances. In the experiments without metabolic activation, the 
cells were exposed for 2 hr before bromodeoxyuridine was added. The incubation then 
continued for an additional 24-hr period. The medium was removed and the cells were rinsed 
before new medium with bromodeoxyuridine and colchemid was added for an additional 2-hr 
culture period. A  similar design was used in the experiment with S9, but the medium containing 
the test substance and the metabolic system was replaced after 2 hr of exposure. After cell 
harvest and fixation on slides, the cells were stained with Hoechst 33258. Selection of 
cells for scoring was based on well-spread chromosomes with good morphology. The total 
number of chromosomes analyzed for SCEs was over 1,000 for each concentration of 
chlorobenzene.
Chlorobenzene was found to induce a dose-related increase of SCEs in both experiments 
without S9. Chlorobenzene was reported to be slightly insoluble and toxic at the concentrations 
that gave the increased incidence of SCEs (in experiment one: 300 and 500 |ug/ml; in 
experiment two: 500 and 1,000 pg/ml), but there were no significant decreases in the number 
of M2 cells. Chlorobenzene did not increase the number of SCEs in the presence of S9 up to 
a dose of 300 jag/ml (a concentration that was clearly toxic to the cells).
In a review of the genotoxicity of hexachlorobenzene and other chlorinated benzenes (18), it 
was stated that monochlorobenzene failed to actively induce SCEs in a cultivated human cell 
line. Since no reference was given to the original paper, it has been impossible to evaluate and 
judge the validity of this information. Chlorobenzene has also been tested and reported 
negative for induction of SCEs in an earlier study on CHO-cells than that reported above. In 
this EPA sponsored, unpublished study by Loveday (cited in reference 60), chlorobenzene 
was tested at lower concentrations than those employed in the more recent study presented 
above.
Chlorobenzene was reported to induce reciprocal recombination in the yeast S. cerevisiae, 
strain D3. The number of recombinants/105 survivors was increased when chlorobenzene was 
tested at concentrations of 0.05 or 0.06% in the presence of a metabolic activation system (32). 
However, since these findings originate from an unpublished report from 1979 by Simmon, 
Riccio, and Peirce, it has not been possible to evaluate the significance of the reported 
“positive” finding. No studies were available on the ability of chlorobenzene to induce other 
types of genetic effects such as reciprocal exchanges between homologous chromosomes, gene 
conversion, gene amplification, insertional mutations, etc.
8.6 Cell Transformation and Tumor Promotion
Cell transformation tests may provide some information of the ability of chemicals to induce 
neoplastic transformation of cultured somatic cells. These tests do not generally provide any
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direct information on the molecular mechanisms of action that could be either genotoxic or 
epigenetic. Chlorobenzene has apparently been tested in such an assay (29). Cultured adult rat 
liver cells were exposed to various concentrations of chlorobenzene: 0, 0.001, 0.005, 0.05, or 
0.01%. The cells were exposed 12 times. Each exposure lasted 16 hr with sufficient time to 
recover from toxicity between each exposure. It was reported that chlorobenzene induced a 
low, but definitive, anchorage independency in the cells, indicating an ability of the substance 
to induce cell transformation in vitro. This study, originating from the American Health 
Foundation, has apparently not been published. The information was obtained from a con­
densed abstract in the TSCATS database and it has consequently not been possible to evaluate 
the data in great detail.
The ability of chlorobenzene and other halogenated benzenes to promote hepatocarcinogenesis 
has also been evaluated in a rat liver foci bioassay (45). The end point of the assay (i.e., the 
occurrence of altered foci of hepatocytes in vivo) is considered to show putative preneoplastic 
lesions. Male and female Sprague-Dawley rats were subjected to a partial hepatectomy before 
being given an oral dose of the liver tumor initiator diethylnitrosamine (0.5 mmole/kg b.wt.). 
One and five weeks after the injection of the carcinogen, groups of rats (5-7 animals) were 
given an i.p. injection of 0.5 mmole chlorobenzene/kg b.wt. (the total amount corresponding 
to 112 mg/kg). Two weeks after the final injection, the rats were sacrificed. Pieces of the liver 
were removed and stained for the presence of T-glutamyltranspeptidase activity (GGT-foci). 
In contrast to 1,2,4,5-tetrachlorobenzene and hexachlorobenzene, monochlorobenzene was 
reported to be without tumor promoting activity in male and female rats. However, since the 
data were presented in a summarized form only, without any indication of having been 
subjected to statistical analysis, it is difficult to judge the significance of the reported findings. 
The G GT foci/cm2 was, for example, 0.67 ± 0.31 (mean ± SEM) for male rats given 
chlorobenzene; 0.17 ± 0.15 for male controls given tricaprylin and 1.20 ± 0.34 for male rats 
given 1,2,4,5-tetrachlorobenzene (judged “positive”).
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9 CARCINOGENICITY
The potential carcinogenicity of chlorobenzene has been tested in rats and mice but no 
epidemiological data were available with regard to its carcinogenic effects in humans.
9.1 Animal Studies
In a 2-year cancer bioassay on male and female F344/N rats and B6C3F1 hyurid mice, groups 
of 50 males and 50 females were given chlorobenzene by gavage, 5 days/week for 103 weeks 
(51, 68). Rats and female mice were given 0 (com oil; vehicle), 60 or 120 mg/kg b.wt./day; 
and male mice were given 0, 30, or 60 mg/kg/day. The highest doses used differed by factors 
of 2-4 from those required to produce severe tissue injury in the previously mentioned 
subchronic toxicity studies (see p. 24). Also included in the study were 50 untreated animals 
of each sex and species (untreated controls). The animals were observed daily for mortality, 
and those animals appearing moribund were sacrificed. Complete necropsies were performed 
on all animals and a number of tissues were taken for histopathological examination.
The administration of chlorobenzene for 2 years did not significantly affect the body weights 
of the animals, and there were no overt clinical signs of toxicity. Although the survival rates 
were slightly reduced in some chlorobenzene-treated groups, a closer analysis showed that 
this was not due to the compound. The only tumor type found to occur at a statistically 
significant increased frequency in the chlorobenzene-exposed animals was neoplastic nodules
Table 3.— Frequencies of liver tumors in male rats given 
chlorobenzene orally up to 2 years (51, 52, 68)
Type of tumor






60 mg/kg/day 120 mg/kg/day
Neoplastic nodules
overall incidence 4/50 2/50 4/49 8/49
incidence after 2 years 2/34 0/39 4/32 7/26
Neoplastic nodules + carcinoma
overall incidence 4/50 4/50 4/49 8/49
incidence after 2 years 2/34 2/39 4/32 7/26
*Tumor incidence at terminal sacrifice (after 2 years of exposure)
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in the livers of male rats in the highest dose group. The increased incidence was significant 
by dose-related trend tests, and by pair-wise comparisons between the vehicle controls and 
the highest dose group. Neoplastic nodules are of a benign nature, and the only hepatocellular 
carcinomas diagnosed among the male rats affected two control animals.
The tumor incidences in the male and female mice and in the female rats given chlorobenzene 
for 2 years did not exceed those in the corresponding vehicle or untreated controls. However, 
although not being a significant effect, two rare tumor types were also observed in rats given 
chlorobenzene: transitional-cell papillomas of the urinary bladder (one male in the low dose 
group, and one male in the high dose group) and a tubular-cell adenoma of the kidney (one 
female rat in the high dose group). The historical incidences of these tumors in Fischer F344/N 
rats were, at the time of the study, 0/788 for transitional cell-papilloma of the urinary bladder 
in com-oil-treated males, and 0/789 for renal tubular-cell adenocarcinoma in female controls 
given com oil.
The conclusion that chlorobenzene caused a slight increase in the frequencies of male rats with 
neoplastic nodules of the liver has been challenged, mainly for statistical reasons (77). The 
authors of the cancer study disagreed with most of the criticisms, but said that the increased 
incidence of benign liver tumors in male rats should be considered only as equivocal evidence 
of carcinogenicity, not sufficient to conclude that chlorobenzene is a chemical carcinogen (52). 
Using their weight of evidence classification scheme (30), the U.S. EPA rated chlorobenzene 
in Group D: inadequate evidence of carcinogenicity (6, 33).
In a summary of the results from 86 different 2-year carcinogenicity studies conducted by 
NTP, Haseman et al. (41) divided the various studies into four different categories: studies 
showing carcinogenic effects (43/86), studies with equivocal evidence of carcinogenicity 
(5/86), studies showing no carcinogenic effects (36/86), and inadequate studies (2/86). The 
increased incidence of neoplastic nodules in the livers of male rats was regarded as evidence 
showing carcinogenic effects of chlorobenzene. However, no attempt was made to distinguish 
between “clear” and “some” evidence of carcinogenicity (these agents were pooled into one 
group).
9.2 Epidemiological Studies
Two different surveys of cancer mortality rates for U.S. counties revealed an increased 
mortality rate from bladder cancer in some northwestern counties in Illinois during the periods 
1950-69 and 1970-79; these surveys resulted in a bladder cancer incidence study in eight of 
the counties incorporated in that region (61). Eligible cases were those diagnosed with bladder 
cancer during the period of 1978 and 1985. Age-adjusted standardized incidence ratios (SIRs) 
were calculated for each county and for the 97 zip codes within these counties. When the data 
were analyzed, only two zip codes were found to have an elevated risk level, and one of these, 
with a total population of 13,000 inhabitants in 1980, had a significantly increased risk for 
bladder cancer in both males (number of cases: 21; SIR: 2.6; 95% confidence interval: 1.1-2.6) 
and females (number of cases: 10; SIR: 2.6; Cl: 1.2-4.7).
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Since it was revealed that there could have been a potential environmental exposure to 
trichloroethylene, tetrachloroethylene, benzene, and other organic solvents from the drinking 
water wells used by that community, a follow-up cross-sectional etiologic study was initiated 
(74). No risk factors unique to the reported cluster, such as smoking and occupation, could be 
identified, and the only factor that stood out was the fact that most of the cases had lived in 
the community for twenty years or more [K. Mallin, personal communication]. With regard 
to the potential environmental exposure to chlorobenzene, this was probably insignificant, 
since no trace of the compound was ever found in the community wells themselves, even 
though it was found in the landfill close to the wells.
There are no case reports or epidemiological studies available concerning the potential 
carcinogenicity of chlorobenzene in humans.
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10 TERATOGENICITY AND REPRODUCTIVE TOXICITY
Data on the potential teratogenicity and reproductive toxicity of chlorobenzene are limited to 
findings obtained in experimental animals. From these experiments there were no indications 
of any teratogenic effects. However, there was some evidence of embryotoxicity, but only at 
doses of chlorobenzene that also affected the adult animal. The biological consequences of 
these effects are difficult to interpret. No adverse effects on reproductive performance or 
fertility have been observed in animals exposed to chlorobenzene.
10.1 Teratogenicity
Until now, there have been no reports on chlorobenzene-induced adverse effects on human 
fetal development available in the literature. The experimental data on the potential 
embryotoxicity and teratogenicity of chlorobenzene derives from an inhalation teratology 
study in rats and rabbits (48). The study, which was performed by Dow Chemicals, also exists 
in an unpublished version (44). The results have been reported elsewhere in, for example, a 
review of teratological data on several industrial chemicals (49).
Adult virgin female Fischer F344 rats were mated with adult males of the same strain (48). 
Groups of 32 to 33 bred females were then exposed to 0, 75, 210, or 590 ppm (0, 345, 966, or 
2,714 mg/m3) chlorobenzene vapor for 6 hr/day, from day 6 through day 15 of gestation. The 
animals were sacrificed on day 21 of gestation. The number of dams examined varied between 
27 and 29. Among the parameters investigated were: maternal body and liver weights, clinical 
signs of toxicity, number and position of fetuses in utero; number of live and dead fetuses; 
number and position of resorption sites; number of corpora lutea; fetal sex ratio, body weight, 
and crown-rump length of each fetus; gross external alterations of the fetuses; and internal soft 
tissue malformations and skeletal alterations. Some evidence of chlorobenzene-induced 
maternal toxicity was observed among the females in the highest dose group: lowered food 
intake, reduced body weight gain, and increased absolute and relative liver weights. However, 
the inhalation of chlorobenzene vapor did not induce any teratogenic effects. The only 
compound-related fetal effect registered was a slight delay in skeletal development of fetuses 
in the highest dose group.
Two separate experiments were performed with pregnant rabbits. Groups of adult female New 
Zealand White rabbits were artificially inseminated and exposed to 0, 75, 210, or 590 ppm 
(experiment 1) and to 0, 10, 30, 75, or 590 ppm (experiment 2) chlorobenzene, 6 hr/day from 
day 6 to day 18 of gestation. Each group consisted of 30 to 32 rabbits. The animals were 
sacrificed on day 29 of gestation. The same types of fetal observations were made as those 
described above for the rats. The number of pregnant animals examined varied between 28
51
and 31. The only evidence of maternal toxicity observed among the rabbits was a significantly 
increased incidence of animals with enlarged livers in the two highest dose groups.
In the first experiment, there was a slightly increased incidence of a variety of malformations 
in all groups examined. Among those were several cases of external and visceral malformations 
scattered among the chlorobenzene exposed groups. There was no apparent trend for a 
dose-related increase in any of the single malformations that occurred, with the possible 
exception of a low incidence of heart anomalies in the highest dose groups (controls: 0/117; 
75 ppm: 0/110; 210ppm: 1/193; and 590ppm: 2/122). With regard to skeletal anomalies, there 
was a significantly increased incidence of fetuses with an extra thoracic rib in the highest dose 
group.
In the second experiment, there was a significantly increased incidence of implantations 
undergoing resorption (showing early embryonic death) in the highest dose group. The 
percentage of litters containing resorptions was 41% in the control group, 48% in the group 
exposed to 10 ppm, 50% in the 30 and 75 ppm groups and 61% in the 590 ppm group. The 
second experiment in rabbits did not show any compound-related increases of any type of 
malformation. Taken together, the experiments performed on the pregnant rats and rabbits 
showed some evidence of embryotoxic effects of chlorobenzene at the highest exposure 
concentration. LOEL with regard to embryotoxicity (delayed skeletal development in rats, an 
extra rib, and possibly also an increased incidence of early embryonic deaths in rabbits) was 
590 ppm (2,714 mg/m3), an exposure concentration that was found to induce toxic effects in 
the adult animal.
John et al. (49) considered that the absence of significant adverse fetal effects in the pregnant 
experimental animals was evidence enough to suggest that the TLV (at that time, 75 ppm in 
the United States) afforded an adequate margin of safety for the unborn human child. In 1986, 
a similar attempt to evaluate the prenatal risks following from occupational exposure to various 
industrial chemicals was made in Germany (85). Chlorobenzene was one of eighteen agents 
considered safe at the occupational exposure limit (at that time, 50 ppm in Germany).
10.2 Reproduction Toxicity
In a final test rule for chlorobenzene, released in July 1986 (31), the U.S. EPA required 
manufacturers and processors of chlorobenzene to conduct reproductive effects testing of 
chlorobenzene to elucidate the potential reproductive hazard of the compound. At that time, 
EPA believed that the information available from general toxicity tests (probably those 
deriving from IBT, see p. 25) on testicular effects in dogs exposed to chlorobenzene, suggested 
a potential reproductive hazard in humans.
To satisfy the need for reproductive effects testing for chlorobenzene, Monsanto Company 
conducted a two-generation reproductive study on rats (67). Groups of 30 male and 30 female 
Sprague-Dawley CD rats (FO-generation) were exposed to 0, 50,150, or 450 ppm (i.e., 0,230, 
690, or 2,070 mg/m3) chlorobenzene vapor for 10 weeks prior to mating and through mating, 
gestation, and lactation. The exposure took place 6 hr/day, 7 days/week. A selected number
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of the offspring from the FO-generation (30 males and 30 females/group) formed the 
FI-generation. These animals were exposed to the same concentrations of chlorobenzene as 
the FO-generation, starting 1 week post-weaning; lasting 11 weeks prior to mating; and through 
mating, gestation, and lactation. The progeny of the FI-generation, the F2-pups, were observed 
during weaning, and then they were sacrificed. A  number of parameters were investigated, 
including body weights, food consumption, mating and fertility indices, pup and litter survival, 
and histopathological examinations of selected organs (liver, kidneys, pituitary gland, and 
male and female reproductive organs).
Table 4.— Frequencies of liver, kidney and testicular lesions in male rats 
exposed to chlorobenzene vapor up to eleven weeks (67)
Organ Lesion Generation 0
Doses (ppm) 
50 150 450
Liver Hepatocellular F0 0/30 0/30 5/30 14/30
hypertrophy 
(minimal to mild)
FI 2/30 0/30 3/30 7/30
Kidney Tubular dilation F0 0/30 4/30 6/30 18/30
(unilateral + bilateral) FI 8/30 7/30 14/30 22/30
Interstitial nephritis F0 1/30 2/30 7/30 10/30
(unilateral + bilateral) FI 1/30 3/30 7/30 11/30
Foci of regenerative F0 0/30 1/30 5/30 8/30
epithelium (unilateral + 
bilateral)
FI 1/30 0/30 5/30 11/30
Testes Degeneration of F0 1/30 0/30 2/30 6/30
germinal epithelium 
(unilateral + bilateral)
FI 1/30 0/30 3/30 6/30
Chlorobenzene did not significantly affect the body weights or food consumption in any of 
the generations studied. However, the histopathological examination showed dose-related 
changes in the livers, kidneys, and testes of F0 and FI males. The hepatotoxicity was 
manifested both as hepatocellular hypertrophy and significantly increased mean and absolute 
liver weights. The lowest LOEL for the latter effect was 50 ppm (i.e., 230 mg/m3), the FO-males 
being most sensitive.
The renal changes appeared as an increased incidence of animals with tubular dilation with 
eosinophilic material, interstitial nephritis, and foci of regenerative epithelium. There was an
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increased incidence of animals with a degeneration of the testicular germinal epithelium among 
the FO-males in the highest dose group (bilateral changes), and FI-males in the two highest 
dose groups (unilateral changes only).
Despite the testicular lesions observed in the male rats of the highest dose groups, there were 
no chlorobenzene-induced adverse effects on the reproductive performance or fertility of the 
adult animals. The maternal body weights during the gestation and lactation were comparable 
with those of the controls, mating and fertility indices were unaffected in both the FO and 
FI-generation, and the pup and litter survival indices for all exposed groups were comparable 
with those of the corresponding controls.
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11 DOSE-EFFECT AND DOSE-RESPONSE RELATIONSHIPS
Tables 5-8 on the following pages summarize the various toxic effects of chlorobenzene. It is 
suggested that the following effects and dose levels should be taken into consideration when 
establishing permissible levels of occupational exposure:
(1) The prenarcotic and irritating effects of chlorobenzene (observed in humans exposed to 
60 ppm for 3-7 hr).
(2) The clear hepatotoxic effects of chlorobenzene (“lowest” LOEL value reported was 
50 ppm in rats exposed for 11 weeks).
(3) The possible hematopoietic toxicity of chlorobenzene (leukopenia was reported in mice 
exposed to 22 ppm for 3 months).
11.1 Acute Exposure
Table 5 summarizes some data obtained in various acute toxicity studies on experimental 
animals. The table also includes some information on the acute toxicity of chlorobenzene in 
humans. However, our knowledge of the acute toxicity of chlorobenzene in humans derives 
almost exclusively from isolated case reports of poisonings or accidental occupational ex­
posures, showing that chlorobenzene may induce significant CNS-depression (i.e., narcotic 
effects such as drowsiness, incoordination, and unconsciousness) at high acute dose exposures. 
Unfortunately, these reports cannot be used for the establishment of dose-effect relationships, 
mainly because they do not include any information on the actual levels of exposures.
The critical effect of acute exposure to chlorobenzene vapors appears to be the prenarcotic 
effects of the substance. An exposure chamber study on five male volunteers exposed to 
60 ppm (275 mg/m3) for 7 hr (71) showed that these concentrations induced acute subjective 
symptoms such as drowsiness, headache, irritation to the eyes, and sore throat. A  significant 
decrease in flicker-fusion values, indicating a lowered perception, was observed after 3 hr of 
exposure to the same concentration of chlorobenzene vapor (71). The information on the 
human recognition odor threshold for chlorobenzene varies, but is probably about 0.68 ppm 
(i.e., 3.1 mg/m3) (3).
11.2 Repeated Exposure
The various effects following repeated exposures of chlorobenzene have been summarized in 
Tables 6-8. Some previously cited studies in this report, are not included in these tables. The 
main reason for this is that they were considered insufficient with regard to information on
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dose-effect and dose-response relationships, thereby preventing a meaningful evaluation of 
NOEL and LOEL values. To get a complete picture of the toxicity of chlorobenzene after 
repeated exposure, the reader is referred to earlier sections of this document.
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Mortality* Oral Rat 1,540 mg/kg 19
Mouse 1,355 mg/kg 66
Rabbit 2,250 mg/kg 19, 32
Guinea pig 5,060 mg/kg 19,32
Man 500-5,000§ mg/kg 92
Mortality* Inhalation Rat 13,870 mg/m3 for 6 hr
19
Mouse 8,822 mg/m3 
for 6 hr
19, 32
CNS-depression (narcosis) Oral Rat 1,540 mg/kg 19,51,68
Oral Mouse 1,000 mg/kg** 51,68
CNS effects 
(prenarcotic effects)
Inhalation Man 275 mg/m3 
for 7 hr
71
Behavioral changes^ Inhalation Mouse 3,700 mg/m3 
for 4 hr§5
24
Liver necrosis i.p. injection Rat 1,100 mg/kg 22
Increased serum ALAT i.p. injection Rat 225-1,100 mg/kg 22
Mild centrilobular changes 
(e.g., cloudy swelling)
i.p. injection Rat 225 mg/kg 22
Decreased hepatic levels of 
glutathione
i.p. injection Rat 225 mg/kg 22
Renal necrosis i.p. injection Mouse 760 mg/kg 75
Increased bile duct flow i.p. injection Rat 562 mg/kg 94
*LD5o/LC5o for mortality; LOEL for other effects (lowest identified values).
Ĝenerally due to respiratory paralysis.
Êstimated probable acute lethal dose in animals.
“ Animals were not subjected to necropsy.
^Acute subjective symptoms (drowsiness, headache, irritations from eyes and sore throat. 
^50% decreased immobility in a behavioral despair swimming test.
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administration Duration Species LOEL NOEL Reference
Increased 
serum levels of 
liver enzymes
Oral 13 weeks Rat 500 mg/kg 250 mg/kg 51,68
13 weeks Dog 54-272 mg/kg 27-54 mg/kg 32,53
Increased total 
liver porphyrin




Oral 2 weeks Rat 2,300 mg/kg not determined 46
13 weeks Rat 125 mg/kg 60 mg/kg 51,68
13 weeks Mouse 250 mg/kg 125 mg/kg 51,68
Inhalation 11 weeks Rat 230 mg/m3 not determined 67





Oral 13 weeks Rat 250 mg/kg 125 mg/kg 51,68
13 weeks Mouse 250 mg/kg 125 mg/kg 51,68
Inhalation 11 weeks Rat 690 mg/m3 230 mg/m3 67
Neoplastic
nodules
Oral 2 years Male rats 120 mg/kg 60 mg/kg 51,68
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Table 7.— Effects of chlorobenzene after repeated exposure: additional toxic effects
Organ/E fTect
Route of 





Oral 13 weeks Rat 500 mg/kg 250 mg/kg 51,68
13 weeks Mouse 250 mg/kg 125 mg/kg 51,68
Tubular dilation, 
interstitial nephritis 
and/or foci of regen­
erative epithelium
Inhalation 11 weeks Rat 690 mg/m3 125 mg/m3 51,68
Lungs 
Increased weight




Inhalation 11 weeks Rat 690 mg/m3 230 mg/m3 67
Thymus 
Lymphoid necrosis




Oral 13 weeks Rat 750 mg/kg 500 mg/kg 51,68
13 weeks Mouse 250 mg/kg 125 mg/kg 51,68
*Bone marrow 
Myeloid depletion
Oral 13 weeks Rat 500 mg/kg 250 mg/kg 51,68
Embryotoxicity Inhalation During
pregnancy
Rat 2,714 mg/m3 966 mg/m 48
During
pregnancy
Rabbit 2,714 mg/m3 3966 mg/m 48
*Zub (97) showed that male and female Swiss mice developed leukopenia after having been exposed to 22 ppm 
(100 mg/m3) chlorobenzene 7 hr/day for 3 months and it has been reported in secondary sources of information 
(32, 92) that Varhavskaya observed various types of pathological changes in the bone marrow of male rats given 
oral doses of 0.01 mg chlorobenzene/kg b.wt./day for 9 months (the significance of the latter study is 
questionable; such low doses have not induced hematopoietic toxicity in any other study).
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administration Duration Species LOEL NOEL Reference
Mortality Oral 14 days Rat 1,000 mg/kg 500 mg/kg 51,68
13 weeks 500 mg/kg 125 mg/kg 51,68
14 days Mouse 1,000 mg/m 500 mg/kg 51,68
13 weeks 125 mg/kg 60 mg/kg 51,68
Inhalation 13 weeks Dog 272 mg/m3 54 mg/m 32,53
Decreased body 
weight gain
Oral 13 weeks Rat 250 mg/kg 125 mg/kg 51,68
99 days Rat 250 mg/kg 50 mg/kg 53
13 weeks Mouse 250 mg/kg 125 mg/kg 51,68
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12 RESEARCH NEEDS
(1) The data on the genotoxic and tumor-promoting effects of chlorobenzene are not consistent. 
This is an area requiring further research, especially with regard to the reported ability of 
chlorobenzene (or more likely of some of its metabolites) to bind covalently to DNA.
(2) The structural resemblance between chlorobenzene and benzene, and the reported 
hematopoietic toxicity of chlorobenzene in experimental animals, call for further studies 
addressing the potential problem with the chlorobenzene-induced bone marrow (i.e., 
hematopoietic) toxicity, especially with regard to potential dose-effect and dose-response 
relationships.
(3) Chlorobenzene has been used in large quantities in industry for several years. However, 
there is still a paucity of data on actual exposure levels of chlorobenzene in occupational 
settings today. A  survey of the potential exposure to chlorobenzene in relevant industries 
is therefore recommended.
(4) There are only limited epidemiological data available on the health status of workers 
chronically exposed to chlorobenzene. Recent data on a limited number of volunteers 
showed, for example, that exposure to chlorobenzene vapors at previous threshold limit 
values (e.g., 75 ppm in the United States and 50 ppm in Germany) can induce prenarcotic 
effects, and animal data show that repeated exposure to chlorobenzene at these levels may 
affect the liver. Information from epidemiological studies examining dose-effect and 
dose-response relationships, especially with regard to the prenarcotic, hepatotoxic and 
possibly also hematopoietic effects of chlorobenzene, would be useful.
(5) Further studies should be made to explore and assess the potential risks from the ex- 
trahepatic bioactivation of chlorobenzene (e.g., in the nasal mucosa).
According to EXICHEM (34), an OECD database on projects on existing chemicals, there are 
ongoing or planned activities in several countries with regard to the evaluation and assessment 
of the potential adverse health and environmental effects of chlorobenzene. Most of these 
activities seem to involve gathering of scientific data on toxicological and ecotoxicological 
effects, monitoring of environmental levels, and health and/or environmental hazard evalua­
tions. It may be worthwhile to note that chlorobenzene has been designated “future high 
priority” by LARC (34).
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13 DISCUSSION AND EVALUATION OF HEALTH EFFECTS
Chlorobenzene (also known as monochlorobenzene or benzene chloride) is 1 of 12 possible 
chemical species in the group of chlorinated benzenes. At room temperature, chlorobenzene 
is a colorless, volatile liquid with an odor that has been described as almondlike, or like that 
of mothballs and benzene. Chlorobenzene is hardly soluble in water, but is freely soluble in 
lipids and various organic solvents.
Chlorobenzene has been used extensively in industry for many years, and its main use is as a 
solvent and intermediate in the production of other chemicals. In occupational settings, the 
main exposure is that following inhalation of chlorobenzene vapors.
Once absorbed, chlorobenzene is rapidly distributed to various organs in the body. Highest 
levels are found in fat, liver, lungs, and kidneys. Chlorobenzene is metabolically activated to 
two different intermediate electrophilic epoxides by cytochrome P450/P448-dependent 
microsomal enzymes. Chlorobenzene is not only bioactivated in the liver, but also in other 
organs and tissues such as the lungs and nasal mucosa. The reactive metabolites of chloroben­
zene are converted either nonenzymatically to various chlorophenols, or enzymatically to the 
corresponding glutathione conjugates and dihydrodiol derivatives. The glutathione conjugates 
are then either eliminated as such, or transferred to even more water-soluble products and 
excreted in the urine as mercapturic acids. The dihydrodiol derivatives are converted to 
catechols and excreted as such in the urine. The absolute quantities and ratios between the 
various metabolites formed differs among various species.
The major human urinary metabolites of chlorobenzene are the free and conjugated forms of 
4-chlorocatechol and p-chlorophenol. It has been recommended that measurements of these 
should be used as biological exposure indicators for monitoring occupational exposure. 
Recommended biological threshold limits at the end of a working shift are 116 mmol of total 
chlorocatechol and 22 mmol total p-chlorophenol per mol creatinine (2).
The toxic effects of chlorobenzene in experimental animals are relatively well documented, 
although many toxicity studies were unpublished reports or written in a language not familiar 
to the evaluator. No major data gaps could be identified, and the majority of the identified 
studies appeared to be of acceptable quality, permitting a meaningful risk identification. The 
amount of human data on the toxicity of chlorobenzene is, however, limited.
The acute toxicity of chlorobenzene in experimental animals is relatively low. The lowest 
acute inhalation LC50 value identified was 8,800 mg/m3 (female mice exposed for 6 hr). The 
acute exposure to high concentrations of chlorobenzene is mainly associated with various 
CNS-effects. These are generally manifested as initial excitation followed by drowsiness,
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adynamia, ataxia, paraparesis, paraplegia and dyspnea. Death is generally a result of 
respiratory paralysis. CNS-depressant effects (drowsiness, incoordination and unconscious­
ness) have also been observed in humans after acute poisoning or occupational exposure to 
high concentrations of chlorobenzene. The human probable oral acute lethal dose of chloroben- 
zene has been estimated at 0.5-5 g/kg b.wt.
An exposure chamber study of five male volunteers exposed to 60 ppm (275 mg/m3) for 7 hr 
showed that this concentration of chlorobenzene induced acute subjective symptoms such as 
drowsiness, headache, irritation to the eyes, and sore throat. A  significant decrease in 
flicker-fusion values, indicating lowered perception, was observed after 3 hr of exposure to 
the same concentration of chlorobenzene vapor. Inhalation of chlorobenzene vapor is irritating 
to the eyes and the mucous membranes of the upper respiratory tract. Prolonged skin contact 
may lead to mild chemical bums.
Repeated administration of chlorobenzene to experimental animals for several weeks or 
months, is mainly associated with various effects in the liver and kidneys. These organs are, 
with the CNS, the primary targets for chlorobenzene-induced toxicity. The hepatotoxicity of 
chlorobenzene is manifested as increased activities of serum liver enzymes, increased liver 
weight, hepatic porphyria and hepatocellular necrosis. Similar effects have also been observed 
in a man who ingested 140 ml of a 90% chlorobenzene solution in a suicide attempt. It may 
be useful to note that there is some evidence from in vitro studies, showing that humans, due 
to metabolic differences, may be more susceptible to the hepatotoxic effects of chlorobenzene 
than rodents. The nephrotoxic action is mainly manifested as increased kidney weight, focal 
coagulative degeneration, and necrosis of the proximal tubules.
Chlorobenzene differs from many polychlorinated aromatic hydrocarbons in not being a 
general inducer of the cytochrome P450/P448 enzyme system. Instead, chlorobenzene appears 
to lower the cytochrome P450 levels. Since administration of chlorobenzene induces an initial, 
but transient, depletion of the glutathione levels in the liver, exposure to this compound seems 
associated with a lowered capacity of both bioactivating and detoxifying enzyme systems.
Repeated administration of chlorobenzene to experimental animals is also associated with 
lesions of the thymus (lymphoid depletion and necrosis), spleen (lymphoid or myeloid 
depletion), bone marrow (leukopenia, myeloid depletion, general bone marrow depression), 
lungs (increased lung weights, necrotic lesions in the bronchial epithelium), and testes 
(bilateral or unilateral degeneration of the germinal epithelium). Of these effects, the 
hematopoietic toxicity is of special interest. When male and female mice were exposed to 100 
mg/m3 (22 ppm) of chlorobenzene, 7 hr/day for 3 months, they were reported to develop 
leukopenia and a general bone marrow depression.
It is generally assumed that the toxic effects of chlorobenzene are mediated by covalent binding 
of reactive metabolites to critical cell structures in the target organs. However, the exact 
molecular mechanisms of action behind the various toxic effects of chlorobenzene are still 
unknown. Several possible toxicological mechanisms may be involved. Whereas, for example, 
the hepatotoxic and nephrotoxic action of chlorobenzene may be a direct result of covalent
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binding to critical structures and/or an indirect effect of oxidative stress, the CNS-depressant 
effect is most likely mediated by other toxicological mechanisms, probably induced by the 
unmetabolized substance itself.
It appears as if halogenated aromatic monocyclics form a complex group when it comes to the 
interpretation of their genotoxicity. In the case of chlorobenzene there is no problem with lack 
of information. At least 12 different published investigations representing various types of 
genetic endpoints and/or test systems were identified. Apart from the published information, 
there are also several unpublished studies mentioned in the present document. Even if some 
results only are presented as a figure or symbol in a summarizing table, the conceivable 
problem with condensed presentations of study designs, protocols and results do not seem of 
major importance in the case of chlorobenzene. There were no obvious differences in study 
qualities between those reporting absence of genotoxic effects and those showing effects.
The major problem in interpreting the existing genotoxicity data for monochlorobenzene 
relates to the fact that the compound was reported “negative” in some test systems, and 
“positive” in others. The interpretation becomes even more complex when one also has to 
consider that whereas some authors reported that chlorobenzene was genotoxic/mutagenic in 
a given test system, other investigators reported a “negative” result. In the case of chloroben­
zene, this seems to be the situation in the L5178Y mouse cell lymphoma assay, the micro­
nucleus test, and when measuring SCEs in vitro (at least when one includes unpublished 
information).
The combination of being positive in an L5178Y gene mutation assay and in a SCE assay and 
simultaneously being negative in the Ames test and in an assay for chromosomal aberrations 
in C H O  cells, is not unique for chlorobenzene (1, 89). However, the mutagenic effect of 
chlorobenzene observed in the L5178Y cells, with and without exogenous metabolic activa­
tion, and its ability to induce sister chromatid exchanges in cultivated Chinese hamster cells 
in the absence of metabolic activation, are not isolated positive responses. Consequently, 
chlorobenzene has also been shown to increase the incidence of micronuclei in bone marrow 
cells of exposed mice in a dose-dependent manner. Although chlorobenzene apparently 
lacked DNA-damaging effects in a rat hepatocyte DNA-repair test, radioactivity from 
14C-chlorobenzene was reported to bind covalently directly to D N A  in various organs, 
including the liver. This was shown in both mice and rats, in vivo as well as in vitro. The 
latter findings suggest that chlorobenzene, or more likely, some of its metabolites, can interfere 
directly with the DNA-molecule.
The data on DNA-binding should be interpreted with some care because it cannot be excluded 
that the relatively low levels of DNA-binding is an artifact resulting from protein contamina­
tion. The reported binding of [14C]chlorobenzene-associated radioactivity to nucleic acids 
deserves particular attention and should be further examined. At present, it is suggested that 
chlorobenzene should be regarded as an agent capable of inducing a certain degree of 
DNA-binding after administration of large doses.
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Beside the above-mentioned “positive” results from various short-term tests, chlorobenzene 
has also been reported to induce point mutations in Actinomyces antibioticus 400, abnormal 
mitotic cell-division in Allium cepa, and reciprocal recombination in Saccharomyces 
cerevisiae. However, the significance of these results remains unclear for various reasons.
Previously, when the number of available genotoxicity studies was limited, it was suggested 
that chlorinated benzenes, including chlorobenzene, appeared to lack significant genotoxic 
properties (18). However, paying attention to more recent findings it may be wise to reconsider 
such a conclusion, or at least to initiate more careful and exhaustive réévaluation of the 
potential genotoxicity of chlorobenzene. Although not always consistent and clear, the overall 
data are judged to show “limited evidence of genotoxicity” of chlorobenzene. This judgment 
is based on the fact that chlorobenzene has been reported “positive” in at least three different 
test systems measuring mutagenicity, chromosomal anomalies, and D N A  damage/DNA-binding, 
at the same time as the majority of test results were reported as “negative.” With regard to the 
question of how potent genotoxic agent chlorobenzene might be, the available “positive” 
studies showed that its genotoxic potential is low. The effects were generally observed only 
after administration of relatively high concentrations of chlorobenzene.
The ability of chlorobenzene to induce neoplastic transformation has also been tested with 
conflicting results. Whereas the compound was found to induce a low, but definite, anchorage- 
independency in cultured rat liver cells, it was without activity in a rat liver foci bioassay. The 
significance of these results remains unclear.
Chlorobenzene induced benign liver tumors in male rats, but was without tumorigenic effects 
in female rats and male and female mice given the compound by gavage, 5 days/week for 
103 weeks (60 or 120 mg/kg b.wt./day). The inadequate/equivocal evidence of carcinogenicity 
in experimental animals, in combination with the limited evidence of genotoxicity from 
short-term tests and the absence of epidemiological data, implies that chlorobenzene, at 
present, should be regarded as an agent not classifiable as to human carcinogenicity.
Animal experiments on the potential teratogenicity and reproductive toxicity of chlorobenzene 
did not show any significant teratogenic potential of the compound. However, there was some 
evidence of embryotoxic effects in both rabbits (skeletal anomalies and an increased incidence 
of early embryonic deaths) and rats (delayed skeletal development), but these effects were 
only seen at doses found toxic to the adult animal (LOEL with regard to embryotoxicity was 
established to 590 ppm (i.e., 2,714 mg/m3). A two-generation reproductive toxicity study in 
rats did not show any chlorobenzene-induced adverse effects on the reproductive performance 
or fertility.
Apparently, chlorobenzene is without immunotoxic effects in mice after multiple exposures 
at 75 ppm (345 mg/m3), and the compound was reported not to induce skin sensitization in a 
maximization test on male guinea pigs.
CNS effects (i.e., prenarcotic effects) are judged to be the most critical effects following acute 
exposure to chlorobenzene vapors. An exposure chamber study involving five male volunteers
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exposed to 60 ppm (276 mg/m3) for up to 7 hr, showed that this relatively low concentration 
of chlorobenzene vapor resulted in acute subjective symptoms such as drowsiness, headache, 
irritation of the eyes, and sore throat.
Based on what is presently known about the various toxic effects of chlorobenzene, the 
hepatotoxic and nephrotoxic (LOEL in the most sensitive species after 11 weeks of inhalation 
was 50 ppm), and possibly also the hematopoietic effects (leukopenia was observed in mice 
after 3 months of exposure to 22 ppm), are judged to be the most critical effects observed after 
exposure to chlorobenzene. Consequently, it is on these effects that various threshold limit 
values should be based.
So far, there is no reliable scientific data showing that oral doses and/or inhalation of air 
concentrations below the indicated LOEL values would induce other types of significant 
adverse effects in experimental animals.
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14 SUMMARY
B. Heilman: NIOH and NIOSH Basis for an Occupational Health Standard: Chlorobenzene. 
Expert Group for Documentation of Occupational Exposure Limits. Arbete och Halsa 1992:31, 
pp. 1-73.
In the present document, relevant data are summarized and evaluated for the purpose of 
establishing permissible levels of occupational exposure to chlorobenzene. Of the various effects 
described, the effects on the central nervous system (prenarcotic effects) of chlorobenzene, 
together with its hepatotoxic effects, should be considered in setting occupational exposure 
limits. At present, there is “limited evidence” indicating that chlorobenzene is genotoxic and 
that it may induce hematopoietic toxicity at relatively moderate doses. It is presently not 
classifiable as to human carcinogenicity. 105 references.
Key-words: Chlorobenzene; occupational exposure limits; CNS effects; hepatotoxicity; 
genotoxicity, hematopoietic toxicity.
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15 SAMMANFATTNING PA SVENSKA
B. Heilman: NIOH and NIOSH Basis for an Occupational Health Standard: Chlorobenzene. 
Expertgruppen for Gransvardesdokumentation. Arbete och Halsa 1992:31, sid 1-73.
I det aktuella dokumentet gors en genomgang och utvardering av den litteratur som befunnits 
vara relevant som underlag for faststallande av ett hygieniskt gransvarde for yrkesmassig 
klorbensenexponering. Av de effekter som beskrivs, bor hansyn tas till klorbensens paverkan 
pa det centrala nervsystemet (prenarkotiska effekter), samt dess levertoxiska effekter, nar de 
hygieniska gransvardena faststalls. For narvarande foreligger aven misstanke om att klorben- 
sen ar en lagpotent genotoxisk substans, och att man inte kan utesluta en paverkan pa 
blodbilden vid relativt mattliga exponeringsnivaer. For narvarande kan man inte med sakerhet 
uttala sig om huruvida klorbensen ar att betrakta som varande en kemisk carcinogen eller ej. 
105 referenser.
Nyckelord: Klorbensen; hygieniska gransvarden; centralnervosa effekter; levertoxicitet; 
genotoxicitet, benmargstoxicitet.
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